

CLINICAL STUDY PROTOCOL

Title: A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren's dry eye disease under treatment with Cyclosporine A (PROTEGO-2 study).

Study Number: NGF0221

Study Name: PROTEGO-2

IND: 115892

EudraCT number: 2021-003749-39

Investigational Product: Cenegermin

Phase of the study: III

Protocol Version - Date: Version No. 5.0 – 16JUN2022

STATEMENT OF CONFIDENTIALITY

Information in this protocol and accompanying documents contains privileged or confidential information that is the property of Dompé farmaceutici s.p.a. It is understood that the information will not be used, divulged, or published without prior written consent of Dompé farmaceutici s.p.a., except to the extent such disclosure is required by applicable laws and regulations.

CONTACT INFORMATION**SPONSOR**

Dompé farmaceutici S.p.A., Via S. Martino 12, 20122 Milan, Italy
Phone: +39.02.583831
Fax: +39.02.58383324

Medical Expert

PPD [REDACTED]
[REDACTED]
[REDACTED]

Chief Medical Officer

PPD [REDACTED]
[REDACTED]
[REDACTED]

Clinical Operations

PPD [REDACTED]
[REDACTED]
[REDACTED]

PPD [REDACTED]
[REDACTED]
[REDACTED]

SAE Reporting

PPD [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

**CLINICAL RESEARCH
ORGANIZATION**

PPD [REDACTED]
[REDACTED]
[REDACTED]

TABLE OF CONTENTS

CONTACT INFORMATION	2
Table of Contents	3
List of Abbreviations and Definitions of Terms	7
1. STUDY SYNOPSIS	9
2. SCHEDULE OF EVALUATIONS.....	16
2.1. BACKGROUND INFORMATION	17
2.1.1. Nerve Growth Factor - Overview	17
2.1.2. Chemical And Formulation Data	17
2.1.3. Rationale for cenegermin (rhNGF) therapy in patients with dry eye	18
2.2. A SUMMARY OF CLINICAL DATA	19
2.3. STUDY RATIONALE	21
2.3.1. Risk assessment/benefit evaluation.....	22
2.3.2. Description of the Investigational Product	23
3. OVERALL STUDY DESIGN AND INVESTIGATIONAL PLAN	24
3.1. STUDY OBJECTIVES.....	24
3.2. STUDY ADMINISTRATIVE STRUCTURE.....	24
3.3. OVERALL STUDY DESIGN.....	24
3.3.1. Rationale for Selection of dose, control group and treatment schedule in the study	25
4. SELECTION OF STUDY POPULATION	27
4.1. INCLUSION CRITERIA	27
4.2. ELIGIBLE EYE.....	30
4.3. ASSIGNMENT OF PATIENT NUMBER.....	30
4.4. RANDOMIZATION	30
4.5. MASKING.....	30
5. STUDY MEDICATION	32
5.1. DESCRIPTION OF PRODUCT.....	32
5.1.1. Presentation of Non Investigational Medicinal Product (NIMP).....	32
5.1.2. Presentation of Investigational Medicinal Product.....	32
5.2. FORMULATION AND PACKAGING	33

5.3.	STORAGE AND HANDLING OF IMP	35
5.4.	DOSE, ROUTE AND SCHEDULE OF IMP ADMINISTRATION	36
5.4.1.	Administration route	36
5.4.2.	Dose regimen	36
5.5.	ACCOUNTABILITY OF THE IMP	36
5.6.	CONCOMITANT MEDICATION.....	37
6.	STUDY PROCEDURE AND ASSESSMENTS	38
6.1.	SCREENING AND RANDOMIZATION VISITS	39
6.2.	STUDY VISITS AND FOLLOW-UP ASSESSMENTS	41
6.3.	EARLY WITHDRAWAL FROM THERAPY OR ASSESSMENT	48
6.3.1.	Primary Reason For Discontinuation From The Study.....	48
6.3.2.	Discontinuation procedures	49
6.3.3.	Replacement procedure.....	50
6.4.	END OF STUDY	50
7.	ENDPOINTS	51
7.1.	STUDY ENDPOINTS	51
7.1.1.	Primary endpoint.....	51
7.1.2.	Secondary endpoints	51
7.1.3.	Exploratory endpoint	51
7.1.4.	Safety endpoint	52
8.	EVALUATION OF ADVERSE EVENTS AND SAFETY INFORMATION.....	53
8.1.	DEFINITIONS.....	53
8.2.	ADVERSE EVENT (AE) MONITORING	55
8.3.	RECORDING	55
8.3.1.	Relationship of AEs to the Investigational Product.....	56
8.3.2.	Severity of AEs.....	56
8.4.	SERIOUS ADVERSE EVENT REPORTING.....	57
8.4.1.	Reporting Procedure for Investigators to Dompé and CRO	57
8.4.2.	Conditions that should not be reported as serious adverse events	58
8.4.3.	Reporting Procedure to the IEC/IRB and to Regulatory Authorities.....	58
8.4.4.	Periodical Reporting to Regulatory Authorities	59
8.5.	UNMASKING OF THE STUDY TREATMENT	60
8.6.	FOLLOW-UP OF PATIENTS WITH ADVERSE EVENTS (AES)	60
8.7.	PREGNANCY IN THE CLINICAL TRIAL.....	61
8.8.	ADVERSE EVENTS CAUSING TREATMENT DISCONTINUATION	61

8.9.	OVERDOSE	61
9.	STATISTICS.....	63
9.1.	SAMPLE SIZE	63
9.2.	ANALYSIS POPULATION.....	63
9.3.	OVERVIEW OF PLANNED STATISTICAL ANALYSES	63
9.4.	STATISTICAL METHODOLOGY	64
9.4.1.	General Considerations.....	64
9.4.2.	Primary Estimand	64
9.4.3.	Analysis of efficacy variables.....	65
9.4.4.	Analysis of exploratory variables	68
9.4.5.	Analysis of safety variables	68
9.4.6.	Subgroup analysis	69
9.4.7.	Missing data.....	69
10.	ETHICAL CONSIDERATIONS.....	70
10.1.	INSTITUTIONAL REVIEW BOARD AND INDEPENDENT ETHICS COMMITTEE.....	70
10.2.	ETHICAL CONDUCT OF THE STUDY	70
10.3.	DATA MONITORING COMMITTEE.....	70
10.4.	PATIENT INFORMATION AND CONSENT	71
10.5.	CONFIDENTIALITY	71
10.6.	COMPENSATION FOR MEDICINE-INDUCED INJURY AND INDEMNIFICATION.....	71
11.	DATA HANDLING AND RECORD KEEPING.....	72
11.1.	CASE REPORT FORMS	72
11.2.	DATA MANAGEMENT	72
11.3.	DOCUMENTATION REQUIRED PRIOR TO INITIATION OF AND DURING THE STUDY	73
11.4.	ESSENTIAL DOCUMENT RETENTION	74
12.	STUDY MANAGEMENT.....	75
12.1.	REGULATORY BODY APPROVAL	75
12.2.	MONITORING.....	75
12.3.	ACCESS TO RECORDS.....	76
12.4.	AUDIT AND INSPECTION	76
12.5.	PROTOCOL AMENDMENTS	76
12.6.	DISCONTINUATION OF THE STUDY	76

12.7.	PUBLICATIONS.....	77
13.	REFERENCE.....	78
14	APPENDICES.....	81
14.1	APPENDIX 1-SPONSOR APPROVAL PAGE	81
14.2	APPENDIX 2-INVESTIGATOR’S SIGNATURE PAGE	82
14.3	APPENDIX 3 AMERICAN-EUROPEAN CONSENSUS CRITERIA FOR SJÖGREN’S SYNDROME	83

List of Abbreviations and Definitions of Terms

ADR	Adverse Drug Reaction
AE	Adverse Event
BCDVA	Best Corrected Distance Visual Acuity
BID	Bis in die (twice a day)
CFR	Code of Federal Regulations
CRA	Clinical Research Associate
CRO	Contract Research Organization
CsA	Cyclosporine A
CSR	Clinical Study Report
DE	Dry Eye
DED	Dry Eye Disease
DHHS	Department of Health and Human Services
DNA	Deoxyribonucleic acid
DSUR	Development Safety Update Report
e-CRF/CRF	Electronic/Case Report Form
EDC	Electronic Data Capture
EMA	European Medicine Agency
ETDRS	Early Treatment Diabetic Retinopathy Study
ETV	Early Termination Visit
FAS	Full Analysis Set
FDA	Food and Drug Administration
FPI	First Patient In
FPFV	First Patient First Visit
FU	Follow Up
GCP	Good Clinical Practice
ICF	Informed Consent Form
ICH	International Conference on Harmonisation
IDEEL	Impact of Dry Eye on Everyday Life
IMP	Investigational Medicinal Product
IRB	Institutional Review Board
IUD	Intra Uterine Device

LNGFR	Low-affinity nerve growth factor receptor
LPLV	Last Patient Last Visit
MedDRA	Medical Dictionary for regulatory activities
mcg/mL	micrograms/millilitre
NEI	National Eye Institute
NIMP	Non-Investigational Medicinal Product
NGF	Nerve Growth Factor
NK	Neurotrophic Keratitis
PI	Principal Investigator
PID	Patient Identification number
PP	Per Protocol Population
PT	Preferred Term
p75NTR	p75 Neurotrophin Receptor
RC	Reading Center
rhNGF	recombinant human Nerve Growth Factor
RP	Retinitis Pigmentosa
SAE	Serious Adverse Event
SAF	Safety population
SANDE	Symptom Assessment iN Dry Eye
SAP	Statistical Analysis Plan
SD	Standard Deviation
SDV	Source Data Verification
SLE	Slit-Lamp Examination
SOC	System Organ Class
SUSAR	Suspected Unexpected Serious Adverse Reaction
TEAE	Treatment Emergent Adverse Event
TFBUT	Tear Film Break-Up Time
TID	Ter in die (thrice times a day)
TrkA	Tropomyosin receptor kinase A
USA	United States of America
Vs	Versus
§	Section

1. STUDY SYNOPSIS

CLINICAL STUDY SYNOPSIS:	
Study Number	NGF0221
Title of Study	A 4-week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren's dry eye disease under treatment with Cyclosporine A (PROTEGO-2 study)
Study Name	PROTEGO-2
IND N°	115892
EUDRACT:	2021-003749-39
Study Centers (Country)	Approximately 10 study sites in Europe and USA
Development Phase	Phase III
Objective	The primary objective of this study is to assess the efficacy and safety of cenegermin ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease (DED).
Study Design and Methodology	This is a phase III, multicenter, double-masked, parallel arm, vehicle-controlled trial.
Number of Patients	Randomization 1:1 of 72 patients to cenegermin ophthalmic solution 20 mcg/mL ter in die (TID) or vehicle ophthalmic solution TID for 4 weeks. Assuming a dropout rate of 10%, up to 80 patients are expected to be enrolled.
Main Inclusion criteria <ol style="list-style-type: none"> 1. Male or female aged ≥ 18 years 2. Patients with a confirmed diagnosis of Sjogren's syndrome or other autoimmune disease known to induce Sjogren's DED. 3. Patients with severe Sjogren's DED characterized by the following clinical features: <ol style="list-style-type: none"> a. Corneal and/or conjunctival staining with fluorescein using National Eye Institute (NEI) grading system ≥ 3 b. Symptom assessment in dry eye (SANDE) questionnaire global score >25 mm c. Schirmer test I (without anaesthesia) between 2 and 5mm/5min, inclusive 4. The same eye (eligible eye) must fulfill all the above criteria 5. Diagnosis of severe Sjogren's DED at least 3 months before enrolment (current use or recommended use of artificial tears for the treatment of Sjogren's related dry eye) 6. Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units (20/200 Snellen value) in each eye at the time of study enrolment 7. If a female of childbearing potential, have a negative urine pregnancy test and use a highly effective method to avoid pregnancy for the duration of the trial and 30 days after the 	

study treatment period. Males of reproductive potential should use effective contraception during treatment and 30 days after the study treatment period

8. Patients who have given written informed consent before any study-related procedures not part of standard medical care are performed.
9. Patients must have the ability and willingness to comply with study procedures.
10. Patients under treatment with topical cyclosporine (CsA), or topical ophthalmic treatments of the same class for at least 30 days before screening visit (day 8).

Main exclusion criteria

1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments
2. Evidence of an active ocular infection, in either eye
3. Presence of any other ocular disorder or condition requiring topical medication during the entire duration of study in either eye
4. History of severe systemic allergy or of ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than due to dry eye (DE)
5. Intraocular inflammation defined as Tyndall score >0
6. History of malignancy in the last 5 years
7. Systemic disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (e.g. current systemic infections) or with a condition incompatible with the frequent assessment required by the study
8. Patient with a history of serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or clinically significant allergy to foods, amide local anesthetics or other materials including commercial artificial tears (in the opinion of the investigator)
9. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
 - a. are currently pregnant or,
 - b. have a positive result at the urine pregnancy test (Baseline/Day 1) or,
 - c. intend to become pregnant during the study treatment period or,
 - d. are breast-feeding or,
 - e. are not willing to use highly effective birth control measures, such as: combined (estrogen and progesterone containing) hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, implantable, injectable), intrauterine device(IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence during the entire course of and 30 days after the study treatment period

<p>10. Any concurrent medical condition, that in the judgment of the PI, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being</p> <p>11. Use of topical corticosteroids, lifitegrast, autologous serum tears in either eye during the study (previous use not an exclusion criteria but must be discontinued at the screening visit)</p> <p>12. Contact lenses, True Tear device, moisture goggles, sutureless amniotic membrane or punctum plug use during the study (previous use not an exclusion criteria but must be discontinued at the screening visit)</p> <p>13. History of drug addiction or alcohol abuse within the last year</p> <p>14. Any prior ocular surgery (including refractive, palpebral and cataract surgery) if within 90 days before the screening visit</p> <p>15. Participation in a clinical trial with a new active substance during the past 3 months prior to screening</p> <p>16. Participation in another clinical trial study at the same time as the present study</p>	
Test/Reference Product, Dosage and Mode of Administration Duration of treatment	<p>Oxervate[®], an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); reference product is vehicle. Test and reference will be instilled in both eyes for 28 consecutive days according to the following scheme:</p> <p>Group 1: one drop of cenegermin 20 mcg/mL will be instilled in both eyes TID (every 6 hours, e.g. 7:00 am, 01:00 pm; 07:00 pm).</p> <p>Group 2: one drop of vehicle will be instilled in both eyes TID (every 6 hours, e.g. 7:00 am, 01:00 pm; 07:00 pm).</p> <p>Both groups will continue with topical CsA eye drops (or other topical ophthalmic treatment of the same class) as previously prescribed at least 15 minutes apart. The investigational medicinal Product (IMP) will be provided in a monthly box containing 28 daily vials. Together with the IMP monthly box, patients will be provided with a sufficient number of pipettes and adaptors for the administration of the IMP.</p>
Study procedures	<p>Patients will be evaluated at screening (day -8), baseline (day 1+2), and week 2 (day 14±2), week 4 (day 28±2) or early exit, week 8 (day 56±2), week 12 (day 84±4), and week 16 (day 112±7) follow-up visits. Safety evaluations will continue until week 24 (day 168 ±7)</p> <p><u>Screening Visit (day -8):</u> all tests/measurements for assessment of eligibility will be performed.</p>

	<p><u>Wash-out period (from day -8 to baseline):</u> 8(+2) days with no further treatment except CsA and commercially available preservative free artificial tears if strictly needed provided by the Sponsor. The use of artificial tears will be tracked in the patient's diary.</p> <p><u>Treatment:</u> eligible patients will be randomized 1:1 and treated for 4 weeks with either cenegermin ophthalmic solution 20 mcg/mL or vehicle.</p> <p>The experimental IMP and CsA or analogue class are allowed during the treatment period however, if strictly needed, the patient may use commercially available preservative free artificial tears provided by the Sponsor. The use of artificial tears will be tracked in the patient's diary.</p> <p><u>Follow up:</u> Initially 8 weeks (from week 5 to week 12) post treatment with no further topical ocular treatment except CsA and commercially available preservative-free artificial tears provided by the Sponsor and administered TID.</p> <p>Furthermore, the patient can administer additional artificial tear eye drops provided by the Sponsor only if strictly needed, and must document in the patient's diary the number of additional drops administered for each eye.</p> <p>Patients will then be followed up for efficacy and safety endpoints until week 16 and for safety endpoints until week 24.</p> <p>During the follow up period from week 13 until week 24, other topical treatments will be allowed at discretion of the treating physician in addition to CsA. Such treatments will be recorded by the investigators.</p> <p>Patients can continue any systemic treatment as required to control their autoimmune disease throughout the study; any change in systemic treatments must be recorded by the investigators.</p> <p>Maximum total study duration: 112±7 days for efficacy evaluations plus an additional 56±7 days for safety evaluations.</p>
Study population	Patients with severe Sjogren's DED will be included. A total of 80 patients will be enrolled assuming a 10% drop out rate to yield 72 eligible patients.
Co-Primary Efficacy Endpoints	<ul style="list-style-type: none"> Schirmer I test (without anesthesia) >10mm/5min at week 4 in the eligible eye. Change from baseline in Symptoms questionnaire (SANDE) global score at week 12

Secondary Efficacy Endpoints	<ul style="list-style-type: none"> • Change from baseline in Schirmer I test (without anesthesia) [Time frame: week 4, 8, 12 and 16]; • Change from baseline in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) [Time frame: week 4, 8, 12 and 16]; • Change from baseline in Tear Film Break-Up Time (TFBUT) [Time frame: week 4, 8, 12 and 16]; • Change from baseline in symptoms questionnaire (SANDE) scores for severity and frequency [Time frame: week 8, 12 and 16]; • Number of patients experiencing worsening in symptoms scores (SANDE) and/or NEI score $\geq 50\%$ assessed at week 4; • Quality of life (IDEEL) questionnaire [Time frame: week 4, 8, 12 and 16].
Exploratory Endpoints	<ul style="list-style-type: none"> • Proportion and frequency of preservative free artificial tears use (n° drops/day) during the treatment period; • Frequency of preservative free artificial tears use (n° drops/day) during the follow up period; • Change from baseline in Schirmer I test (without anesthesia) Vs week 2; • Change from baseline in symptoms questionnaire (SANDE) global score [Time frame: week 2 and 4]; • Change from baseline in symptoms questionnaire (SANDE) scores for severity and frequency [Time frame: week 2 and 4]; • Change from baseline in Cornea and conjunctiva vital staining with fluorescein (NEI scales) Vs week 2; • Change from baseline in TFBUT Vs week 2; • Number of patients experiencing a worsening in symptom scores (SANDE) and/or NEI score $\geq 50\%$ assessed at week 2; • Change from baseline in Schirmer test II (with topical Anesthesia) vs Week 4. • Change from baseline in BCDVA
Safety Endpoint	<ul style="list-style-type: none"> • Incidence and frequency of Adverse Events (AEs) and Treatment-emergent adverse events (TEAEs), assessed throughout the study.

Statistical Methods	<p>The sample size of the study is calculated based on results from previous studies. Expecting a difference of 42% in Schirmer I rate of responders (defined as patients reaching a value >10mm/5min) at Week 4 and a difference of >10 points in global SANDE score improvement from baseline at week 12 in favour of the treated group, a total sample size of 72 evaluable patients (80 pts considering 10% drop-out rate) allows to achieve an overall power of >90% to show superiority of cenegermin ophthalmic solution vs. vehicle in terms of the primary endpoints, considering a one-sided alpha of 0.025.</p> <p>Summary statistics are defined for quantitative variables (number of observations, mean, standard deviation, median, minimum and maximum) and qualitative variables (number and percentage per category). If appropriate, confidence intervals around the mean or the proportions will be presented.</p> <p>The proportion of patients reaching a value of Schirmer I test (without anesthesia) >10mm/5min at week 4 will be analyzed by means of logistic regression. The change from baseline in SANDE global score at week 12 will be analyzed by means of an adjusted ANCOVA procedure.</p> <p>If the analysis of co-primary endpoints leads to rejection of the null hypothesis, key secondary endpoints will be tested in a conditional sequential manner to show superiority of cenegermin versus placebo vehicle according to the pre-defined ranking sequence. Independent of the results on co-primary endpoints, all secondary endpoints will be analysed at each available time point by means of descriptive statistics and by appropriate parametric tests. Data record in the questionnaires of quality of life will be presented with appropriate descriptive statistics and processed with appropriate inferential test. Change from baseline value and shift tables versus baseline may be summarized for all available post-baseline visits.</p> <p>Explorative endpoints will be descriptively summarized at each available time point. Any statistical testing will be descriptive in nature. Correlation between sign and symptom scores will be assessed.</p> <p>AEs will be coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA). Individual AEs will be</p>
----------------------------	--

	<p>listed in patient data listings. TEAEs will be presented in terms of the number of AEs and incidence by treatment, seriousness, relationship to treatment, severity, and study period (treatment or follow-up).</p> <p>The Safety (SAF) and the Full Analysis Set (FAS) population will consist of all patients who will be randomized and received at least one dose of the investigational medicinal product (IMP). Safety population will be analyzed according to the actual treatment received; FAS population will be analyzed according to ITT principle, i.e. by treatment allocation. The Per Protocol (PP) population will consist of all patients in the FAS population who do not have major protocol deviations. Primary and secondary efficacy analyses will be conducted on the FAS population while SAF and PP populations will be used for safety and sensitivity analyses, respectively.</p> <p>The Statistical Analysis Plan (SAP) will be issued before database lock with more technical and detailed elaboration of the principal features of statistical analyses. Any deviation from the original statistical plan will be described in the Clinical Study Report (CSR).</p>
--	---

2. SCHEDULE OF EVALUATIONS

Study procedures	Screening (Day-8)	Visit 1 Baseline* (Day 1 + 2 days)	Visit 2 Week 2 ^a (Day 14 +/- 2 days)	Visit 3 End of treatment Week 4 ^a (Day 28 +/- 2 days)	Visit 4 follow-up Week 8 ^a (Day 56 +/- 2 days)	Visit 5 follow-up Week 12 ^b (Day 84 +/- 4 days)	Visit 6 follow-up Week 16 ^c (Day 112 +/- 7 days)	Visit 7 follow-up Week 24 ^c (Day 168 +/- 7 days)
Explanation to the patient of study aims, procedures and possible risks	X							
Informed Consent	X							
Inclusion/Exclusion Criteria	X	X						
Pregnancy Test	X	X		X			X	
Randomization		X						
Demographics	X							
Ocular and Systemic Medical History	X							
Previous Ocular And Systemic Medications	X	X						
SANDE	X	X	X	X	X	X	X	
IDEEL	X	X	X	X	X	X	X	
BCDVA	X	X	X	X	X	X	X	
External Ocular Examination	X	X	X	X	X	X	X	
Schirmer test I	X	X	X	X	X	X	X	
Slit Lamp Examination	X	X	X	X	X	X	X	
TFBUT	X	X	X	X	X	X	X	
Fluorescein staining (NEI scale)	X	X	X	X	X	X	X	
Schirmer test II (with Anesthesia)		X		X				
Study drug dispensation		X ^d						
Preservative free artificial tears dispensation	X	X	X	X	X			
Verify patient study medication dosing compliance				X				
Concomitant Ocular And Systemic Medications	X	X	X	X	X	X	X	X

Study procedures	Screening (Day-8)	Visit 1 Baseline* (Day 1 + 2 days)	Visit 2 Week 2 ^a (Day 14 +/- 2 days)	Visit 3 End of treatment Week 4 ^a (Day 28 +/- 2 days)	Visit 4 follow-up Week 8 ^a (Day 56 +/- 2 days)	Visit 5 follow-up Week 12 ^b (Day 84 +/- 4 days)	Visit 6 follow-up Week 16 ^c (Day 112 +/- 7 days)	Visit 7 follow-up Week 24 ^c (Day 168 +/- 7 days)
Frequency of preservative free artificial tears use (n° drops/day)		X	X ^e	X ^e	X ^f	X ^f	X	X
Dispensation, check and retrieval of patient's diary	X ^g	X	X ^h	X	X ^h	X	X ^h	X ⁱ
Recording of AEs	X	X	X	X	X	X	X	X

*) visit window of +2 days; a) Visit window of ± 2 days; b) Visit window of ± 4 days; c) Visit window of ± 7 days; d) a monthly box will be given to the patients; e) During the treatment period patients can use, if strictly needed, the preservative free artificial tears provided by the Sponsor; f) During the follow up period it is allowed to use the preservative free artificial tears provided by the Sponsor ; g) At screening visit only dispensation h) During visit 2, week 2, and visit 4, week 8, and visit 6 – week 16 the PI or a delegate must only check if the patient has correctly completed the diary; i) At Visit 7 – week 24 only check and retrieval.

2.1. BACKGROUND INFORMATION

2.1.1. Nerve Growth Factor - Overview

Nerve growth factor (NGF) is a polypeptide essential for the survival and growth of sympathetic and sensory neurons, and for differentiation of neurons in the central nervous system. It binds with at least two classes of receptors: high-affinity tropomyosin receptor kinase A (TrkA), a transmembrane tyrosine kinase, and low-affinity NGF receptor (LNGFR), also known as p75 neurotrophin receptor (p75NTR).

NGF and TrkA are expressed in the anterior segment of the eye (iris, ciliary body, lens, cornea and conjunctiva), and NGF is released in the aqueous humor. Several pieces of experimental evidence suggest that NGF affects all tissues of the anterior ocular segments, playing a crucial role in the physiopathology of several anterior ocular segment diseases.

2.1.2. Chemical And Formulation Data

As recombinant human NGF (rhNGF) production in mammalian cells does not achieve adequate yields, a manufacturing process based on the use of recombinant *Escherichia coli* (*E. coli*) has been developed. However, because the biological activity of NGF relies on the formation of three disulfide bonds, and because disulfide bonds cannot occur in the reducing cytosol, the purification and renaturation of NGF produced in *E. coli* is problematic. Based on the knowledge that the prosequence increases the yield and rate of refolding of NGF, we have developed a manufacturing process starting from proNGF. After expression of proNGF in *E.*

coli, the insoluble protein is isolated in the form of insoluble inactive aggregates (inclusion bodies), solubilized in a strong denaturing agent and subsequently converted into the natural conformation, which is determined by the disulfide bridges present in the natural NGF. Biologically active rhNGF is finally obtained by splitting off the prosequence by enzymatic cleavage. The deoxyribonucleic acid (DNA) sequence of human proNGF has been optimized for E coli expression (codon adjustment) and two changes in the furin cleavage site, R101V and K103A, have been introduced. These two changes are important to ensure a homogeneous rhNGF preparation during the process with the mature protein starting with serine 105.

Oxervate® ophthalmic solution contains cenegermin, a recombinant form of human nerve growth factor produced in *Escherichia coli*.

2.1.3. Rationale for cenegermin (rhNGF) therapy in patients with dry eye

Dry eye (DE) is a chronic condition of the ocular surface with severe symptoms and visual impairment, leading to worse efficiency to perform duties for an average of 184 work days and resulting in an average loss of productivity estimated in 5,000USD per year per patient¹.

DE results from systemic diseases (Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, Stevens-Johnson syndrome, thyroid disease), ocular conditions (meibomian gland dysfunction, blepharitis, ocular rosacea, corneal dystrophies), elective surgeries (refractive surgery, blepharoplasty), eyelid conditions (lagophthalmos, entropion/ectropion), cranial surgeries, side effects of drugs (antihistamines, diuretics, beta-blockers), ocular injuries and burns, chemotherapy and radiation, aging, menopause².

DE pathogenesis is multifactorial however, a number of common mechanisms can be identified: (i) chronic inflammation of the conjunctiva; (ii) decrease of ocular surface sensitivity; (iii) impairment of quantity of tears and/or quality of the tear film, including tear film hyperosmolarity; (iv) changes of conjunctival epithelium with squamous metaplasia and decrease of goblet cell density; (v) corneal epithelium damage².

Until now, treatment has been limited to the use of artificial tears to temporarily improve lubrication of the ocular surface, immunomodulation to increase tear production and decrease inflammation [Cyclosporine (CsA), Lifitegrast], or the use of topical steroids to decrease the inflammatory reaction acutely. However, chronic use of steroids is associated with several complications such as cataract development and increasing intraocular pressure². CsA is a topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Lifitegrast ophthalmic solution is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED); by inhibiting the LFA-1/ICAM-1 interaction it is presumed to limit the formation of an immunological synapse resulting in T-cell inhibition.

On the other hand, experimental and clinical evidence suggests that NGF may affect all the pathogenic mechanisms of DE, potentially restoring ocular surface homeostasis³. Human corneal epithelium, keratocytes, and endothelium produce NGF, and express its high affinity tyrosine kinase receptor A (TrkA), and experimental studies demonstrated that the activation of TrkA receptors by NGF plays a key role in corneal sensory nerve survival⁴.

Indeed, several studies have shown that NGF is involved in the regulation of tear film production. In fact, NGF, TrkA and p75, as well as other neurotrophins (NTs) and related receptors, are expressed by the rat

lacrimal gland tissue; moreover, NGF has been quantified in human tears, indicating that NGF is basally released by the lacrimal gland⁵⁻⁷. These data suggest that NGF may play a role in the maintenance of the tear film and in its alterations in drying ocular surface diseases. Specifically, considering that NGF potentially affects all the components of the ocular surface (cornea, conjunctiva, lacrimal gland, and sensory innervation), it might play an important role during DED. In line with this hypothesis: NGF topical administration in a dog experimental model of DE has been shown to increase tear production, conjunctival goblet cell density and corneal transparency^{2,8}; an increased tear concentration of NGF has been reported in patients affected by keratoconjunctivitis sicca^{9,10}; NGF stimulates glycoconjugate secretion by conjunctival goblet cells, without affecting cell proliferation¹¹.

In several systemic autoimmune conditions, including Sjogren syndrome, the lacrimal gland can be attacked by the immune system resulting in an ocular manifestation of aqueous deficient DE (ADDE)¹². In fact, the leading cause of ADDE in dogs is immune-mediated lacrimal gland dysfunction comparable to Sjogren syndrome in humans¹³. In addition, NGF was found to increase secretory mucin MUC5AC secretion by conjunctival goblet cells, without affecting cell proliferation¹¹. The major secretory gel forming mucin MUC5AC plays a crucial role in the maintenance of a wet-surfaced ocular surface phenotype, in the clearance of debris from the ocular surface epithelia (including pathogens and allergens), and in the stability of the tear film, contributing to preventing its premature evaporation^{14,15}. The underlying tear film dysfunction discussed thus far encompasses alterations in one, or all, of its layers (i.e. the aqueous, mucin, and lipid layer). Tear production is controlled by the lacrimal functional unit (LFU) consisting of the cornea, conjunctiva, lacrimal glands, meibomian glands, and the neuronal network that connects them¹⁴. When corneal nerves are stimulated, afferent signals are triggered through the ophthalmic branch of the trigeminal nerve (V). In turn, efferent secretomotor nerve endings stimulate lacrimal glands, meibomian glands and conjunctival goblet cells to secrete aqueous, lipids and mucin contents of the tear film, respectively¹⁴⁻¹⁶. Likewise, when corneal sensory nerves are stimulated, they release neuromediators that provide trophic support for the corneal epithelium and keratocytes. These corneal epithelial cells and keratocytes release neuropeptides, neurotrophins and growth factors (e.g. NGF) that influence survival, differentiation, and maturation of nerve fibers¹⁷. Thus, neurosensory abnormalities play a key etiological role in DE that remains largely unaddressed by current approved therapeutics.

Specifically, considering that NGF potentially affects all the components of the ocular surface (cornea, conjunctiva and goblet cells, lacrimal gland, and sensory innervation), it may play an important role in Sjogren's (DED). In addition, considering the mechanism of action of NGF in improving ocular surface sensory nerve function, which will induce in turn an improvement in reflex tear secretion and blink rate, it is expected that the effects on both signs and symptoms of DE may be long-lasting.

2.2. A SUMMARY OF CLINICAL DATA

Cenegermin has previously been studied in healthy volunteers and in different subject populations.

In the completed Phase I study in healthy volunteers (study CCI [REDACTED]), a total of 58 subjects (out of 74 enrolled) were treated with single and multiple doses of different concentrations of cenegermin ophthalmic solution showing a good safety profile.

Furthermore, a Phase I/II multicenter, double-masked, vehicle-controlled study evaluating the safety and efficacy of cenegermin at 10 and 20 mcg/mL six times a day in 174 patients with stage 2 and 3 of Neurotrophic Keratitis (CCI [REDACTED]) was completed in 2015; the study demonstrated that cenegermin was very well tolerated and effective in patients with NK. A successful confirmatory study (CCI [REDACTED]) was completed in 2016 and marketing authorization for cenegermin 20 mcg/mL ophthalmic solution was granted by the EMA in July 2017 for treatment of moderate to severe NK. While in the US cenegermin was approved by FDA in 2018 for all stages of Neurotrophic Keratitis. Cenegermin is distributed under the trade name Oxervate® 20 mcg/mL ophthalmic solution.

In addition to NK, cenegermin ophthalmic solution has been evaluated in a Phase I/II study in retinitis pigmentosa patients at 60 and 180 mcg/mL dosages (CCI [REDACTED]), and in a phase I/II study in glaucoma at a dose of 60 mcg/mL (CCI [REDACTED]). An open label, uncontrolled study showed that 4 weeks treatment with cenegermin ophthalmic solution at 20 mcg/mL and 4 mcg/mL concentrations was safe and effective in improving symptoms, corneal staining and tear production in patients with dry eye disease (CCI [REDACTED]). These results prompted two additional phase II randomized clinical trials in patients with DED (CCI [REDACTED]) and in those with ocular discomfort symptoms following refractive surgery (CCI [REDACTED]); these also confirmed the favourable tolerability profile of cenegermin ophthalmic solution at a concentration of 20 mcg/mL when used up to 6 times daily for 8 weeks.

In the double-masked vehicle-controlled Phase II study CCI [REDACTED] no major differences were observed in efficacy when comparing the two administration regimens (6 vs. 2 times/day) and treatment durations (8 weeks vs. 4 weeks) in a subset of patients with similar characteristics (hyposcretive dry eye with Schirmer test <10mm/5min).

An additional phase II study (CCI [REDACTED]) was specifically designed to further prove this hypothesis. It was a 4 week, Phase 2, multicenter, randomized, double-masked, vehicle-controlled, parallel group study with 12 weeks of follow-up to evaluate safety and efficacy of cenegermin ophthalmic solution versus vehicle, in patients with moderate to severe dry eye, started in 2018 in patients with hyposcretive dry eye (with or without an evaporative component caused by the reduced tear film), including patients diagnosed with primary Sjogren syndrome.

In this phase II trial a total of 261 patients were randomized 1:1:1 to receive either cenegermin ter in die (TID) (i.e. 3 times/day), or cenegermin bis in die (BID - i.e. 2 times/day), or vehicle.

The primary endpoint of the study was the change from baseline in Schirmer I test (without anaesthesia), while key secondary endpoints included change from baseline in SANDE scores for severity and frequency, cornea and conjunctiva vital staining, TFBUT and quality of life. Despite the primary endpoint at $p < 0.025$ was not reached in the overall population, the study has clearly shown a superior efficacy of both cenegermin arms versus placebo, especially considering that due to the Covid-19 emergency recruitment was interrupted when only 261 (the minimum number required) out of the 300 patients initially planned were randomized. However, when analyzing the percentage of patients achieving more than 10 mm in Schirmer I test scores at the end of treatment, as pre-specified in the statistical analysis plan (SAP), the difference between both cenegermin dose regimens vs. placebo was statistically significant for both study groups ($p = 0.028$ for cenegermin TID and $p = 0.007$ for cenegermin BID [P-value versus Vehicle TID based on Fisher's exact test]). It is noteworthy that, while no clear dose ranging effect was observed on the tear function endpoints, symptoms recorded by the DE-specific and validated SANDE questionnaire showed a significant persistence of the beneficial effect of the higher dose-regimen (TID) over time and up to the full 16 weeks after the end of the 4 weeks treatment

cycle. In fact, statistical significance vs. vehicle was reached at all follow-up timepoints for the TID with best result at week 12 ($p=0.002$ based on t-test; missing data imputed by LOCF). In addition, no difference was observed in the safety and tolerability profile of the experimental treatment. Specifically, up to 3 instillations per day of cenegermin ophthalmic solution in both eyes confirmed to be safe and well tolerated. The two cenegermin study groups have shown a similar tolerability. No serious adverse events were reported in the study. Adverse reactions were mild and transient, and occurred only during the 4-weeks treatment period of the 16-weeks cycle.

The results of these three randomized controlled studies in DED patients, as well as the results on reflex tear secretion obtained in the neurotrophic keratitis trials CCI and CCI, suggests that cenegermin may be a safe and effective treatment option for patients with hyposecretive/aqueous tear-deficient dry eye disease. In all studies rhNGF was well tolerated and the reported ocular AEs were generally transient and mostly mild and moderate in intensity during the controlled treatment period and the follow-up period.

In the Phase I, randomized, double-masked, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of rhNGF eye drops in healthy volunteers of Japanese ethnicity (study CCI), a total of 30 subjects were enrolled. Twenty subjects were treated with a single dose of cenegermin ophthalmic solution at a 20 mcg/mL concentration and a total of 10 subjects were treated with vehicle. On day 1 patients received only one dose of cenegermin, then the remainder of the trial they received one drop six times a day. Both the single and multiple doses of cenegermin delivered topically as ophthalmic solution were safe and well tolerated by healthy subjects of Japanese ethnicity. No clinically important changes in ECG were observed after dosing with cenegermin. There was no apparent relationship between treatment and plasma cenegermin levels, and this study did not give any indication for an immunogenic potential of cenegermin in humans after ophthalmic treatment.

2.3. STUDY RATIONALE

The data reported above, together with the evidence of cenegermin ophthalmic solution effectiveness in the treatment of patients affected by corneal epithelial defects and ulcers, and moderate to severe DE make cenegermin a strong candidate for the treatment of severe Sjogren's DED^{4,10,18}.

NGF addresses the neurosensory abnormalities associated with DE that are pivotal to restoring ocular surface homeostasis and tear film stability. Sjogren's DE is a complicated consortium of clinical characteristics driven by many factors, and most patients are on chronic topical therapy. Additionally, as noted previously, the pathogenesis of DE is multifactorial, and while NGF potentially affects many of these mechanisms. CD4⁺ T cell-mediated inflammation has been well established to play a role in dry eye disease¹⁹. Various studies have demonstrated that in patients with DE there are increased levels of CD4⁺ T cells and inflammatory mediators such as IL-6, TNF- α , IL-2, IFN- γ and IL-17 in the tears and conjunctiva²⁰. The inflammatory component of DE is believed to drive symptoms in these patients, which is typical why you see patients on various topical medications targeting various pathways. Topical CsA is an immunomodulatory calcineurin-inhibitor that blocks T cell infiltration, activation, and thus, the downstream release of pro-inflammatory mediators including cytokines and chemokines that are involved in the pathogenesis of dry eye¹⁹⁻²¹. The utilization of NGF in Sjogren's DE patients in conjunction with chronic treatment with topical CsA could represent an approach targeting the different mechanisms of the disease.

Additionally, The T cell inhibiting function of CsA is thought to be the key driver for symptomatic relief in patients with DED. In a survey of 5,884 patients, a statistically significant reduction in symptom severity was observed after treatment²². Interestingly, mixed results have been reported regarding CsA improvement in the signs of DE. For example, even though CsA 0.05% emulsion is indicated to increase tear production, lack of replication in individual pre-specified primary efficacy endpoints between the two Phase III trials²³. This coincides with a review of 30 randomized control trials with a total of 4009 participants and follow-up periods ranging from 6 weeks to 12 months on the effectiveness of CsA, both 0.05% and 0.09%, in the treatment of DE by de Paiva et al. The authors concluded that the evidence as to whether or not CsA provides benefit for tear production was inconsistent and of low certainty²⁴. As summarized above, CsA can improve symptoms but does not significantly impact tear production. Therefore, the efficacy of NGF in this study will be primarily assessed by evaluating sign of dry eye through tear production (Schirmer 1). Since the patients enrolled have severe disease with significant lacrimal insufficiency, we cannot physiologically expect an increase of 10mm or more in Schirmer I scores as communicated in the FDA's guidance– Dry Eye: Developing Drugs for Treatment . Therefore, improvement in DE symptoms will also be evaluated as a co-primary endpoint to determine whether there is an added benefit of NGF in severe Sjogren's DE.

2.3.1. Risk assessment/benefit evaluation

This study is considered a low-risk interventional trial. It is conducted with a previously tested dose of medicinal product already authorized and commercialized for the treatment of NK in Europe, US and China. The proposed study is conducted in patients with severe Sjogren's DED, under treatment with CsA administered as clinical practice under authorized indication. Sjogren's DED is an indication for which Oxervate® (cenegermin) ophthalmic solution is not yet approved, however two preliminary clinical studies were already conducted in patients with DE demonstrating that cenegermin is well tolerated in this condition. The risk of this study is comparable to the risk of the standard of care, in fact the dose proposed in this protocol is cenegermin 20 mcg/mL three drops per day instilled in each eye, which is well below the dose approved for the treatment of NK (cenegermin 20 mcg/mL six drops/eye per day).

In particular, based on the approved Oxervate® SmPC the interactions with other drugs might be reduced if cenegermin is administered first, using 15 minutes apart, with the exception of agents known to inhibit epithelial healing (e.g. corticosteroids or eye drops containing preservatives such as benzalkonium chloride, polyquaternium-1, benzododecinium bromide, cetrimide and other quaternary ammonium derivatives). As systemic absorption of cenegermin after use of the medicinal product is negligible or not detectable, no drug interactions are anticipated.

On top of the above, in ciclosporin SmPC (brand name IKERVIS) is described that no interaction studies have been performed with IKERVIS and combination with other medicinal products that affect the immune system co-administration of IKERVIS with eye drops containing corticosteroids could potentiate the effects of ciclosporin on the immune system.

Based on these SmPCs description, and because no corticosteroids are administered, no interactions are expected in this clinical trial.

Considering what is discussed above, no particular safety risks are foreseen with respect to the safety profile of the marketed product Oxervate® (cenegermin 20 mcg/mL ophthalmic solution).

The patients with severe Sjogren's DED participating in this study may potentially benefit from the application of cenegermin for 28 days (4 weeks).

Any possible risk derived from the administration of cenegermin in the specific population involved in this study will be minimized by integrated monitoring which includes clinical observations, Ocular examination, laboratory tests.

2.3.2. Description of the Investigational Product

The investigational medicinal product (IMP) consists of a sterile isotonic solution for ophthalmic administration, containing cenegermin 20 mcg/mL as drug substance.

The matching placebo consists of the vehicle of cenegermin (sterile isotonic solution).

Further information is given in section 5.

3. OVERALL STUDY DESIGN AND INVESTIGATIONAL PLAN

3.1. STUDY OBJECTIVES

The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered TID for 4 weeks in patients with severe Sjogren's DED who are under treatment with topical Cyclosporine A (or other drugs of the same class).

3.2. STUDY ADMINISTRATIVE STRUCTURE

This study will be performed at approximately 10 study centers located in the USA and Europe. At each study center, the Principal Investigator (PI) will be responsible for ensuring that the investigation is conducted according to the signed Investigator agreement, the protocol, GCP guidelines, and local regulations.

The PI at each study center will be responsible for the management of the study, which will consist of maintaining the study file and the patient records, corresponding with the IRB/EC, completing the electronic case report forms (eCRFs) and reporting SAEs within 24 hours of initial awareness.

The PI is responsible for supervising any individual or party to whom the investigator delegates trial related duties and functions conducted at the trial site.

If the investigator/institution retains the services of any individual or party to perform trial-related duties and functions, the investigator/institution should ensure this individual or party is qualified to perform those trial-related duties and functions and should implement procedures to ensure the integrity of the trial-related duties and functions performed and any data generated.

3.3. OVERALL STUDY DESIGN

This is a 4-week phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of cenegermin ophthalmic solution at 20 mcg/mL solution versus vehicle, in patients with severe Sjogren's DED who are under treatment with topical Cyclosporine A (or other drugs of the same class). Patients will be evaluated as per Section 2 "SCHEDULE OF EVALUATIONS".

During the screening (day-8) all procedures for inclusion will be performed. From the day of screening the patients will stop any kind of further treatment, except CsA and commercially available preservative free artificial tears provided by Sponsor for a period of 8 days and 10 days as maximum: day -8 until the baseline visit (day 1+2); Figure 1. At the end of the wash out period (day -8 to baseline), patients meeting the entry criteria for this study will be randomized 1:1 and treated for 4 weeks with either cenegermin ophthalmic solution 20 mcg/mL TID or vehicle TID.

In addition to topical CsA eye drops (both groups will continue with topical CsA eye drops, or other topical ophthalmic treatment of the same class, as previously prescribed), during the 4 weeks of masked treatment only the administration of IMP is allowed. Nevertheless, if strictly needed, the patient can take preservative

free artificial tears (provided by the Sponsor). The use (n° drops/day) of preservative free artificial tears will be clearly documented in a patient's diary and in the eCRF.

Eight weeks post treatment with no further topical ocular treatment except CsA and commercially available preservative-free artificial tears provided by the Sponsor TID will follow the completion of the double-blind treatment. During this follow up period, the patient can administer additional preservative-free artificial tear eye drops, provided by Sponsor, only if strictly needed, and must document in the patient's diary the number of additional drops administered for each eye.

Patients will then be followed up for efficacy and safety endpoints until week 16 and for safety endpoints until week 24. During the follow up period after week 12 until week 24 other topical treatments, in addition to CsA, will be allowed at discretion of the treating physician. Such treatments will be recorded by the investigators. Throughout the study, the patient can continue any systemic treatment as required to control their autoimmune disease, and any change in systemic treatments must be recorded by the investigators.

The total duration of the study is 25 weeks including 1 week of screening.




Figure 1. Study duration

3.3.1. Rationale for Selection of dose, control group and treatment schedule in the study

The dose proposed in this study (cenegermin 20 mcg/mL) has already been tested both in healthy volunteers for five consecutive days (CCI [REDACTED]) and in patients affected by several ocular surface diseases, including moderate to severe DE (CCI [REDACTED]).

Cenegermin 20 mcg/mL (one drop in each eye six times daily for 8 weeks), was also tested in the Phase I/II studies in NK (CCI [REDACTED]), DE (CCI [REDACTED]) and in patients after cataract and refractive surgery (CCI [REDACTED]).

Cenegermin 20 mcg/mL (one drop in each eye TID for 8 weeks) was also tested in the Phase II study (CCI [REDACTED]) in moderate to severe DE.

Cenegermin 20 mcg/mL administered TID, demonstrated to be safe and well tolerated (CCI [REDACTED]), will also ensure the lubrication of the ocular surface in the present study where the use of artificial tears will be not allowed during the treatment period, according to the Investigator.

Higher doses of rhNGF (up to 180 mcg/mL) were administrated to patients with diseases of the back of the eye, such as retinitis pigmentosa (Study CCI [REDACTED]) for up to 168 days.

The 20 mcg/mL concentration of cenegermin is well sustained by the current manufacturing process and is used in a commercial formulation.

A dose regimen of a drop TID of cenegermin ophthalmic solution and a treatment duration of 4 weeks has been selected based on the results of the previous clinical trials described above.

The administration of a total of 3 drops per day for both the study arms has been chosen to guarantee to patients randomized to the vehicle arm to have the minimum amount of lubrication that is compatible with symptoms' relief. A double-blind study design was adopted to minimize systematic bias. Randomization is expected to minimize patient selection bias and increase baseline comparability between treatment groups. The use of placebo control is critical to the study design, providing an accurate estimate of the additive benefit of pharmacotherapy.

The use of the drug's vehicle as placebo helps in making the latter as indistinguishable from the cenegermin solution.

Patients with insufficient therapeutic response, tolerability issues, or worsening of symptoms may be discontinued at any time during the study.

4. SELECTION OF STUDY POPULATION

Patients ≥ 18 years with severe Sjögren's DED will be included. A total of 80 patients will be enrolled (including a 10% of dropout rate).

The safety and efficacy of cenegermin ophthalmic solution will be investigated in these patients.

4.1. INCLUSION CRITERIA

To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria:

1. Male or female aged ≥ 18 years
2. Patients with a confirmed diagnosis of Sjögren's syndrome or other autoimmune disease known to induce Sjögren's DED.
3. Patients with severe Sjögren's DED characterized by the following clinical features:
 - a. Corneal and/or conjunctival staining with fluorescein using National Eye Institute (NEI) grading system ≥ 3
 - b. SANDE questionnaire >25 mm
 - c. Schirmer test I (without anaesthesia) $\geq 2 \leq 5$ mm/5min
4. The same eye (eligible eye) must fulfill all the above criteria
5. Patients diagnosed with severe Sjögren's DED at least 3 months before enrolment (current use or recommended use of artificial tears for the treatment of Sjögren's related DE)
6. Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units (20/200 Snellen value) in each eye at the time of study enrolment
7. If a female of childbearing potential, have a negative urine pregnancy test and use a highly effective method to avoid pregnancy for the duration of the trial and 30 days after the study treatment period . Males of reproductive potential should use effective contraception during treatment and 30 days after the study treatment period
8. Patients who have given written informed consent before any study-related procedures not part of standard medical care are performed.
9. Patients must have the ability and willingness to comply with study procedures.
10. Patients under treatment with topical cyclosporine (CsA), or topical ophthalmic treatments of the same class for at least 30 days before screening visit (day -8).

EXCLUSION CRITERIA

1. Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments
2. Evidence of an active ocular infection, in either eye

3. Presence of any other ocular disorder or condition requiring topical medication during the entire duration of study in either eye
4. History of severe systemic allergy or of ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis and/or keratitis other than dry eye
5. Intraocular inflammation defined as Tyndall score >0
6. History of malignancy in the last 5 years
7. Systemic disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (e.g. current systemic infections) or with a condition incompatible with the frequent assessment required by the study
8. Patient had a serious adverse reaction or significant hypersensitivity to any drug or chemically related compounds or had a clinically significant allergy to drugs, foods, amide local anesthetics or other materials including commercial artificial tears (in the opinion of the investigator)
9. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
 - a. are currently pregnant or,
 - b. have a positive result at the urine pregnancy test (Baseline/Day 1) or,
 - c. intend to become pregnant during the study treatment period or,
 - d. are breast-feeding or,
 - e. are not willing to use highly effective birth control measures, such as: combined (estrogen and progesterone containing) hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, implantable, injectable), intrauterine device(IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence - during the entire course of and 30 days after the study treatment periods
10. Any concurrent medical condition, that in the judgment of the PI, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being
11. Use of topical corticosteroids, lifitegrast, autologous serum tears in either eye during the study (previous use not an exclusion criteria but must be discontinued at the screening visit)
12. Contact lenses, True Tear device, moisture goggles, sutureless amniotic membrane or punctum plug use during the study (previous use not an exclusion criteria but must be discontinued at the screening visit)
13. History of drug addiction or alcohol abuse in the last 2 years
14. Any prior ocular surgery (including refractive, palpebral and cataract surgery) if within 90 days before the screening visit

- 15. Participation in a clinical trial with a new active substance during the past 3 months
- 16. Participation in another clinical trial study at the same time as the present study.

4.2. ELIGIBLE EYE

Should all the inclusion/exclusion criteria be met in both eyes, the worse eye (eligible eye) will be determined **at the baseline visit using** a stepladder approach, as follows:

1. Schirmer's Test (since this is the primary endpoint)-Worse eye will be determined as eye with lower Schirmer I score.
2. NEI score (cornea+conjunctival staining) - If Schirmer I score is the same in both eyes, worse eye will be determined by NEI score (cornea+conjunctival staining).

If all of the above are identical, determination of the worse eye will be based on the Investigator's judgement, otherwise **simply use the right eye** as the eligible eye.

4.3. ASSIGNMENT OF PATIENT NUMBER

Each patient who provides written consent to participate in this study will be assigned a unique 5-digit PID number (e.g. 01-001) consisting of a 2-digit study center number followed by the 3-digit screening number assigned sequentially by each study center, from 001 to 100.

4.4. RANDOMIZATION

Eligible patients will be randomized in a 1:1 ratio to either cenegermin ophthalmic solution 20 mcg/mL TID (~40 patients) or vehicle ophthalmic solution TID (~40 patients).

Each randomized patient will be allocated to a randomization number, according to the stratified randomization list. Drop outs after randomization will not be replaced.

Randomization will be stratified by site to ensure balanced assignment across treatment groups. The stratified permuted block randomization list will be generated with a computer procedure by an independent statistician not involved in the conduct of the study.

Randomization will be performed through IRS. Each Patient Kit number will be randomly associated with a treatment group. The randomization list will be provided to the facility responsible for IMP packaging/labelling for the purpose of IMP preparation.

The enrollment of patients will be scheduled in order to assure an inclusion (eligible to the randomization) of approximately 80 patients to ensure at least 72 evaluable patients (randomized and treated), assuming up to 10% dropout rate.

4.5. MASKING

The identity of the treatments will remain unknown to the patient, Investigator, site staff and Sponsor's clinical research personnel until the completion of the study (after full data base lock), except in case of specific events that will require unmasking of the patient, as detailed below.

The vials containing cenegermin (20 mcg/mL) or vehicle will be identical in appearance, and the contents of the vials will be indistinguishable. All staff directly involved in the analysis of study results will remain masked to treatment assignments while the study is in progress.

A list of sequential kit numbers will be generated by an independent statistician not involved in the conduct of the study. Each kit number will be randomly associated with a treatment group. Patients will be assigned to treatment in numerical order. A tear-off label from the Patient kit box, with the kit number, will be attached to the investigational product dispensing log.

The investigator will be provided with a protected access to the randomization list so only in case of a medical emergency the Investigator can open the treatment allocation for a specific patient.

Also Dompé's Pharmacovigilance contact person will be provided with a protected access to randomization list, so if required by the Pharmacovigilance activities the Pharmacovigilance contact person can open the treatment allocation for a specific Patient.

In the event of a medical emergency where the knowledge of patient treatment is required to provide the patient with appropriate care, Investigators will have the possibility to unmask the treatment assignment for that specific patient. The Investigators are encouraged to contact the CRO staff before becoming unmasked if there is sufficient time.

If the Investigator becomes unmasked for any reason, this information will be recorded on source data and in the eCRF of the study, specifying the date and the reason.

Unmasking events will be recorded and reported in the final study report.

5. STUDY MEDICATION

5.1. DESCRIPTION OF PRODUCT

5.1.1. Presentation of Non Investigational Medicinal Product (NIMP)

TEST PRODUCT NIMP	Blink® Tears or equivalent preservative-free artificial tears
Pharmaceutical form	Lubricating Eye Drops
Administration	<p>One drop of Blink® Tears or equivalent will be instilled in both eyes during the screening week, only if strictly needed by the patient. The patient must document in the patient's diary the n° of additional drops administered for each eye</p> <p>One drop of Blink® Tears or equivalent will be instilled in both eyes during the 4 weeks of masked treatment, only if strictly needed by the patient. The patient must document in the patient's diary the n° of additional drops administered for each eye.</p> <p>One drop of Blink® Tears or equivalent will be instilled in both eye TID (morning, afternoon and evening) during the initially 8 weeks of follow up. The patient, only if strictly needed, can administer additional drops and must document in the patient's diary the n° of additional drops administered for each eye.</p>
Administration route	Ocular

5.1.2. Presentation of Investigational Medicinal Product

TEST PRODUCT IMP	Cenegermin (rhNGF 20 mcg/mL) and/or Placebo (Vehicle ophthalmic solution).
Manufacturer active substance	Dompé Farmaceutici S.p.A., Italy

Manufacturer
finished product

CCI [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Pharmaceutical form

Ophthalmic sterile solution

Dose

Test and reference will be instilled in both eyes for 28 days (4 weeks) according to the following scheme:

Group 1: one drop of cenegermin 20 mcg/mL will be instilled in both eyes three times daily (every 6 hours, e.g. 7:00 am, 01:00 pm; 07:00 pm).

Group 2: vehicle: one drop of vehicle ophthalmic solution will be instilled in both eyes three times daily (every 6 hours, e.g. 7:00 am, 01:00 pm; 07:00 pm).

Administration route

Ocular

5.2. FORMULATION AND PACKAGING

The Investigator will be provided with a subject monthly box containing 4 weekly boxes of frozen IMP solutions ($-20 \pm 5^{\circ}\text{C}$) that, in-turn, contain 7 daily vials to be stored in refrigerator at $2-8^{\circ}\text{C}$ (36°F to 46°F) or at room temperature not exceeding 12 hours. Each vial contains:

- cenegermin, at concentrations of 20 mcg/mL, and/or
- vehicle (placebo).

Together with the IMP monthly box, the patients will be provided with a sufficient number of pipettes, adapters and wipes to be used for the administration of the IMP.

Pipettes, adapters and wipes will be provided separately in single sterile packages and may be kept at room temperature.

The vial adapter is a device for safe transfer of drug between vial and pipette. The pipette is used with an adapter consisting of a connecting device with dual connections: one end for the pipette and one end for the vial. The patient will need to:

1. Put the adapter on the top of the vial (after removing the plastic seal) by piercing the septum

2. Put the pipette on adapter inlet
3. Draw the solution contained in the vial with the pipette until this reaches its capacity
4. Remove the pipette and use it as a dropper to administer one drop of IMP into each eye.

5.3. STORAGE AND HANDLING OF IMP

The Pharmacist and/or Investigator will be responsible for receipt, proper storage, and usage of study drug, as well as for the IMP distribution, collection of used and unused vials and final disposal of the remaining IMP.

The investigational product must be stored at -20 ± 5 °C at the investigational sites, in an appropriate locked room accessible only to the pharmacist, the Investigator, or a duly designated person.

A temperature probe and data logger will accompany the drug on shipment. It is essential that the investigational sites will verify the temperature excursion during shipment vs. the acceptable storage conditions, in order to identify potential stability concerns during shipment. These must be immediately communicated to the Sponsor that will decide upon appropriate actions to be taken. The IMP will be stored in a locked place, sheltered from light. The vials will be not shaken since agitation of vials may cause foaming and/or particle formation.

On Day 1 (baseline visit), the study personnel will give to the patient the monthly boxes containing the study medications.

Patient should bring the study medication, one monthly box at home as soon as possible and immediately store it in a freezer at -20 ± 5 °C.

The weekly box must be kept at 2-8°C for 7 days protected from light; the daily vial can be kept at room temperature, before the patient will use the single vial for each instillation (both eyes) as long as 12 hours are not exceeded. Agitation of vials may cause foaming and/or particle formation. Drug preparation and administration instructions will be provided separately to the site and to the patients.

Together with the IMP monthly box, the patient will also receive a separate administration kit of vial adapters (one per vial), pipettes (3 per vial) and disinfectant wipes (3 per vial); some spare samples could be provided to ensure product administration.

IMP ophthalmic solution leaflet instruction will be provided to patients.

Patients will use one vial to instill one drop in both eyes (**group 1**: cenegermin TID; **group 2**: vehicle TID) three times a day (approximately every 6 hours), starting in the morning when they wake up, for a total duration of 4 weeks⁴ weeks.

The contents of each vial are for the daily administration to both eyes only. After the last administration the used vial should be returned to the original medication box and is not to be reused.

Any deviations from the recommended storage conditions should be immediately reported by the pharmacist to the Sponsor and Investigator, and the use of the drug should be suspended until they have given authorization for its continued use. The IMP supplies are to be used only in accordance with this protocol. The Investigator will not use any drug samples for other purposes (e.g., treating patients or deviating from the protocol with regard to dose regimen, duration of treatment, etc.). Under no circumstances will the Investigator give any drug samples to a third party.

5.4. DOSE, ROUTE AND SCHEDULE OF IMP ADMINISTRATION

5.4.1. Administration route

The Administration route is topical ophthalmic application.

5.4.2. Dose regimen

In all patients both eyes will be treated for a period of 4 weeks.

The dosing scheme of the different study groups is summarized below:

Group 1: one drop of cenegermin 20 mcg/mL will be instilled in both eyes three times daily (every 6 hours, e.g. 7:00 am, 01:00 pm; 07:00 pm).

Group 2: one vehicle drop will be instilled in both eyes three times daily (every 6 hours, e.g. 7:00 am, 01:00 pm; 07:00 pm).

During the 4 weeks of masked treatment only the administration of IMP and CsA eye drops, or other topical ophthalmic treatment of the same class, is allowed. Nevertheless, if strictly needed, the patient can take a preservative free artificial tears (provided by the Sponsor). The use (n° drops/day) of preservative free artificial tears will be clearly documented in a patient's diary and in the eCRF.

Both the patients and the investigator will be masked to the study treatment.

Information about the study drug administration, and comments, will be recorded on the appropriate page of the eCRF.

5.5. ACCOUNTABILITY OF THE IMP

The Pharmacist and/or Investigator will confirm the receipt of the IMP supply in writing by signing and dating standard drug accountability forms.

The Pharmacist and/or Investigator will keep a cumulative inventory and dispensing records, and will maintain all supplies under adequate security.

An accurate drug disposition record will be kept, specifying the date and amount dispensed to each patient.

Adequate record of receipt and use or loss of drug will be retained. This inventory record must be available for inspection by the Sponsor and regulatory inspection at any time. Copies of this record will be provided to the Sponsor by the CRO throughout the duration of the study.

At the week 4 (end of treatment) visit, the patient will return the used or unused study boxes/vials to the Investigator.

At the scheduled visit, the patient diary should be reviewed by the Investigator with the patient for completeness. Missing information should not be provided during the diary check but reported as missing.

During the course of the study and until its conclusion, the Investigator will complete the drug accountability forms. Partially used or unused study drug boxes will be verified by the Investigator and within one month after completion of the trial the partially used and unused study medication will be shipped to the Sponsor or will be destroyed after authorization by the Sponsor or by an authorized company according to GCP regulations.

5.6. CONCOMITANT MEDICATION

As a general rule, in addition to the standard chronic treatment with topical CsA (or other ophthalmic treatment of the same class) that will not be discontinued to participate in the study, no ophthalmic medication other than study drug will be given to the patient from the screening day until all of the final study evaluations have been completed, except for preservative free artificial tears provided by the Sponsor.

IMP should be administered first and concomitant medications should be administered as follows:

- Topical CsA eye drops (or other topical ophthalmic treatment of the same class) as previously prescribed at least 15 minutes apart
- Preservative free artificial tears provided by the Sponsor at least 15 minutes apart

The preservative free artificial tears will be provided by the Sponsor and can be used according to the following scheme:

- 1) During the 4 weeks of masked treatment, only if strictly needed, the patient will instill one drop in both eyes.
- 2) During the 8 weeks of Follow-up period post-treatment one drop will be instilled in both eyes TID (morning, afternoon and evening).

The use (n° drops/day) of preservative free artificial tears will be clearly documented in the patient's diary and eCRF.

All medications (including over-the-counter drugs, herbal products, vitamins, and antacids) taken within 4 weeks prior to the start of and throughout the study will be clearly documented on the Concomitant Medications eCRF page.

Medication entries should be specific to product name (if a combination drug product) and spelled correctly. The dose, unit, frequency, route of administration, start date, discontinuation date, and indication should also be recorded. For medications administered only one time, the frequency column may reflect "once."

6. STUDY PROCEDURE AND ASSESSMENTS

The first patient first visit (FPFV) is defined as the 1st visit performed at one of the clinical centers by the 1st screened patient. The last patient, last visit (LPLV) is defined as the last visit performed at one of the clinical centers by the last patient (i.e., the last visit foreseen by the study protocol), independently of whether the patient completed or withdrew from the study. The First Patient In (FPI) is defined as the first randomized patient at one of the clinical centers.

Patients will be evaluated according to the following scheme:

Interventional phase

- Screening visit (day -8),
- Baseline (day 1+2),
- Week 2 (day 14±2),
- Week 4 (day 28±2) or early exit

Follow up visits

- Week 8 (day 56±2)
- Week 12 (day 84±4)
- Week 16 (day 112±7)
- Week 24 (day 168±7)

The schedule of study procedures and assessments is tabulated by visit in the Schedule of Evaluations in § 2.0.

The descriptions of the procedures to be performed at each visit are provided below.

6.1. SCREENING AND RANDOMIZATION VISITS

During the screening visit (day -8) all procedures for will be performed. From the day of screening the patients will stop any kind of further ophthalmic treatment, except CsA or equivalent, until all of the final study evaluations have been completed, except preservative free artificial tears (wash out period from day -8 to baseline, Day 1 +2). The wash out period should not be less than 8 days and more than 10 days.

At the end of the screening period, patients meeting the entry criteria for this study will be randomized 1:1 and treated for 4 weeks with either cenegermin ophthalmic solution 20 mcg/mL TID or vehicle TID.

Slit lamp examination and the fluorescein staining (Corneal and/or Conjunctival staining with Fluorescein) will be performed at different time-points, as specified in the section 2 of “SCHEDULE OF EVALUATIONS” and procedure will be detailed on the informed consent form.

An independent Blinded Reading Center (RC) will also be used to assess the images collected at protocol-specified time points and sent to the RC as specified in the RC procedure manual.

The RC will provide instructions for the slit lamp photography and the fluorescein staining procedures.

	Day	Procedures/Assessments
Screening visit	Day -8	<p>The following procedures will be performed (order below is mandatory):</p> <ul style="list-style-type: none"> ➤ Explanation to the patient of study aims, procedures and possible risks ➤ Informed consent signature ➤ Screening number allocation ➤ Patient eligibility: Inclusion/exclusion criteria evaluation ➤ Pregnancy test for female patients of childbirth potential ➤ Demographic data ➤ Ocular and systemic medical history ➤ Previous and concomitant ocular and systemic medications (prior to start the study) ➤ Ocular examination of both eyes, to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter • TFBUT • Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) ➤ AE collection ➤ Preservative free artificial tears dispensation <p>The Investigator will dispense to the patients the preservative free artificial tears (Blink® Tears or equivalent), provided by Sponsor, to be used only if strictly needed by the patient (the patient must follow the instruction in the product leaflet). The patients will be instructed to enter information of self-administration of Blink® Tears or equivalent (for each administered dose and AE occurrence into the diary. The diary will be given from the PI or delegate during this visit</p>
At home	Day -8 – Day 1+2 (baseline)	<ul style="list-style-type: none"> ➤ Recording any unusual medical conditions - AE monitoring (diary) ➤ Artificial tears use during the wash-out period (diary) <p>Data will be recorded by the patient on the patient's diary.</p>
	Day	Procedures/Assessments

<p style="text-align: center;">Visit 1 Baseline</p>	<p style="text-align: center;"><i>Day 1 +2</i></p>	<p>The following procedures will be performed (order below is mandatory):</p> <ul style="list-style-type: none"> ➤ Pregnancy test for female patients of childbirth potential ➤ Previous and concomitant ocular and systemic medications (prior to start the treatment) ➤ Ocular examination of both eyes to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the eyelid (Meibomian glands), eyelid (erythema), eyelid (edema), lashes, conjunctiva erythema, lens, iris, anterior chamber, corneal horizontal diameter • TFBUT • Ocular surface staining (NEI score – corneal and conjunctival fluorescein staining) • Schirmer test II (with Anesthesia) ➤ Patient eligibility: Inclusion/exclusion criteria evaluation ➤ Randomization ➤ Study drug dispensation ➤ Preservative free artificial tears dispensation ➤ AE collection <p>During visit 1, Day 1+2 or baseline, PI or delegate must check and collect the patient's diary concerning the screening period and provide a new diary for the treatment period. The PI or a delegate must check if patient has correctly completed the diary. If not, the site staff must retrain the patient.</p> <p>The Investigator will dispense to the patients their monthly box containing the study drug for the following 4 weeks together with an adequate number of adapters and pipettes.</p> <p>The Investigator will dispense to the patients the preservative free artificial tears (Blink® Tears or equivalent), provided by Sponsor, to be used only if strictly needed by the patient (the patient must follow the instruction in the product leaflet). After completing baseline evaluation patients will be administered, by PI, with the study treatment as per instructions, and will self-administer at home the subsequent doses. Patients will return to the clinical site on Day 14 (±2) (Week 2, visit 2).</p>
--	--	--

6.2. STUDY VISITS AND FOLLOW-UP ASSESSMENTS

After the first two weeks of treatment the patient will undergo a medical assessment during the visit 2 (week 2).

Following the completion of the double-blind treatment (visit 3, week 4), patients will be followed up for efficacy until visit 6 (week 16) and safety assessments until visit 7 (week 24). During the follow-up period until week 12, patients will not use further ophthalmic treatment except CsA and preservative free artificial tears, provided by Sponsor, one drop instilled in both eyes three times daily (morning, afternoon and evening). The patient, only if strictly needed, can administer additional drops and must document in the patient's diary the n° of additional drops administered for each eye. After week 12 (visit 5), patients will be followed-up for additional 12 weeks until the end of the study (visit 7, week 24) during which patients can use CsA and others artificial tears different from the artificial tears provided by the Sponsor.

Slit lamp examination and the fluorescein staining (Corneal and/or Conjunctival staining with Fluorescein) will be performed at different time-points, as specified in the section 2 of "SCHEDULE OF EVALUATIONS" and procedure will be detailed on the informed consent form.

An independent Blinded Reading Center will also be used to assess the images collected, as described in the previous paragraph.

	Day	Procedures/Assessments
At home	Days 1-14 ±2	<ul style="list-style-type: none"> ➤ Self-administration at home of the IMP, three times daily every 6 h for both eyes (diary) ➤ Recording any new or changes in concomitant medications (diary) ➤ Recording any unusual medical conditions - AE monitoring (diary) ➤ Recording possible use of preservative free artificial tears (diary). <p>Data will be recorded by the patient in the patient's diary.</p>

	Day	Procedures/Assessments
Visit 2 Week 2	Day 14±2	<p>The following procedures will be performed (order below is mandatory):</p> <ul style="list-style-type: none"> ➤ Ocular examination of both eyes to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid – Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter • TFBUT • Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) • ➤ Concomitant ocular and systemic medications ➤ Frequency of patient's artificial tear use during first 2 weeks of treatment (to be reported in eCRF) ➤ AE monitoring <p>During the visit 2, week 2, the patient must bring the diary assigned during the previous visit. The PI or a delegate must check if patient has correctly completed the diary. If not, the site staff must retrain the patient.</p> <p>At completion of the assessment the patient will be discharged and will be asked to return for the end of treatment visit on day 28±2 (Visit 3 week 4).</p> <p>The Investigator will dispense to the patients the preservative free artificial tears (Blink® Tears or equivalent), provided by Sponsor, to be used only if strictly needed by the patient (the patient must follow the instruction in the product leaflet)..</p>
At home	Days 14 ±2– 28 ± 2	<ul style="list-style-type: none"> ➤ Self-administration at home of the IMP, three times daily every 6 h for both eyes (diary) ➤ Recording any new or changes in concomitant medications (diary) ➤ Recording any unusual medical conditions - AE monitoring (diary) ➤ Recording possible use of preservative free artificial tears (diary). <p>Data will be recorded by the patient on the patient's diary.</p>

	Day	Procedures/Assessments
Visit 3 week 4	Day 28±2	<p>The following procedures will be performed (the below order is mandatory):</p> <ul style="list-style-type: none"> ➤ Pregnancy test for female patients of childbirth potential ➤ Ocular examination of both eyes to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid – Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter • TFBUT • Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) • Schirmer Test II (with Anesthesia) ➤ Assessment of compliance to treatment (from patient diary and IMP reconciliation from returned weekly boxes) ➤ Concomitant ocular and systemic medications ➤ Frequency of patient's artificial tear use during the last 2 weeks of treatment (to be reported in eCRF). ➤ AE monitoring ➤ Verify patient study medication dosing compliance <p>During visit 3, week 4, PI or delegate must check and collect the patient's diary concerning the treatment period and provide a new diary for the follow up period. At completion of the assessment the patient will be discharged and will be asked to return for the follow up visit on day 56±2 (Visit 4 week 8). The Investigator will dispense to the patients the preservative free artificial tears (Blink® Tears or equivalent) provided by Sponsor, to be self-administered three times daily, one drop in both eyes during the first 4 weeks of Follow up. The PI or delegate has to explain to the patients that, only if strictly needed, they can administer an additional numbers of drops of Blink® Tears or equivalent, by documenting all information in the patient's diary.</p>
At home	Days 28 ±2– 56 ± 2	<ul style="list-style-type: none"> ➤ Recording any new or changes in concomitant medications (diary) ➤ Recording any unusual medical conditions - AE monitoring (diary) ➤ Artificial tears use during 4 weeks of FU (diary) <p>Data will be recorded by the patient on the patient's diary.</p>

	Day	Procedures/Assessments
Visit 4 Follow up week 8	Day 56± 2	<p>The following procedures will be performed (the below order is mandatory):</p> <ul style="list-style-type: none"> ➤ Ocular examination of both eyes to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid – Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter • TFBUT • Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) ➤ Concomitant ocular and systemic medications ➤ Frequency of patient's artificial tear use during 4 weeks of FU (to be reported in eCRF). ➤ AE monitoring <p>During visit 4, week 8, PI or delegate must check the patient's diary concerning the follow up period.</p> <p>The Investigator will dispense to the patient the preservative free artificial tears (Blink[®] Tears or equivalent) provided by Sponsor, to be self-administered three times daily, one drop in both eyes during the second 4 weeks of Follow up. The PI or delegate has to explain to the patients that, only if strictly needed, they can administer an additional numbers of drops of Blink[®] Tears or equivalent, by documenting all information in the patient's diary.</p>
At home	Days 56 ±2– 84 ± 4	<ul style="list-style-type: none"> ➤ Recording any new or changes in concomitant medications (diary) ➤ Recording any unusual medical conditions - AE monitoring (diary) ➤ Artificial tears use during 4 weeks of FU (diary) <p>Data will be recorded by the patient on the patient's diary.</p>

	Day	Procedures/Assessments
Visit 5 Follow up week 12	Day 84 ± 4	<p>The following procedures will be performed (the below order is mandatory):</p> <ul style="list-style-type: none"> ➤ Ocular examination of both eyes to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid – Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter • TFBUT • Ocular surface staining (NEI score - corneal and conjunctival fluoresce instaining) ➤ Concomitant ocular and systemic medications ➤ Frequency of patient's artificial tear use during 4 weeks of FU (to be reported in eCRF). ➤ AE monitoring <p>During visit 5, week 12, PI or delegate must check and collect the patient's diary concerning the follow up period and provide a new diary for the second follow up period.</p> <p>The Investigator will instruct the patient that during the follow up period (from week 13 to week 24) other topical treatments will be allowed at discretion of the treating physician. Such treatments will be recorded by the investigators.</p> <p>The patient has to register the use other preservative free artificial tears in the patient's diary.</p>
At home	Day 84 ± 4– 168 ± 7	<ul style="list-style-type: none"> ➤ Recording any new or changes in concomitant medications (diary) ➤ Recording any unusual medical conditions - AE monitoring (diary) ➤ Artificial tears use during 4 weeks of FU (diary) <p>Data will be recorded by the patient on the patient's diary.</p>

	Day	Procedures/Assessments
Visit 6 Follow up week 16	Day 112 ± 7	<p>The following procedures will be performed (the below order is mandatory):</p> <ul style="list-style-type: none"> ➤ Pregnancy test for female patients of childbirth potential ➤ Ocular examination of both eyes to be performed by the physician investigator: <ul style="list-style-type: none"> • Assessment by SANDE questionnaire • Assessment by IDEEL questionnaire • Assessment of best corrected distance visual acuity (BCDVA) • External Ocular Examination • Schirmer test I (without anesthesia) • Slit-lamp examination (SLE) to assess the Eyelid - Meibomian glands, Eyelid – Erythema, Eyelid - Edema Lashes, Conjunctiva Erythema, Lens, Iris, Anterior Chamber, Corneal Horizontal Diameter • TFBUT • Ocular surface staining (NEI score - corneal and conjunctival fluorescein staining) ➤ Concomitant ocular and systemic medication ➤ Frequency of patient's artificial tear use during 4 weeks of FU (to be reported in eCRF) ➤ AE monitoring <p>PI or delegate must check the patient's diary concerning the previous follow up period.</p>

Visit 7 Follow up week 24 Final visit or early termination visit (ETV)	<i>Day 168 ± 7</i>	<p>The End of Study (EoS) visit is defined as the last follow-up at week 24. In case of premature study discontinuation, patients will undergo an Early Termination Visit (ETV).</p> <ul style="list-style-type: none"> ➤ Concomitant ocular and systemic medication ➤ Frequency of patient's artificial tear use during 8 weeks of FU (to be reported in eCRF) ➤ AE monitoring <p>PI or delegate must check and collect the patient's diary concerning the last follow up period.</p>
---	--------------------	---

6.3. EARLY WITHDRAWAL FROM THERAPY OR ASSESSMENT

6.3.1. Primary Reason For Discontinuation From The Study

A premature discontinuation will occur when a patient who signed the ICF ceases participation in the study, regardless of circumstances, before the completion of the study protocol procedures. Patients can be prematurely discontinued from the study for one of the following reasons:

- **Adverse event (AE):** Any significant AE that, is not compatible with study continuation especially relating to tolerability of IMP.
- **Disease progression or worsening,** that is not compatible with study continuation especially when indicative of insufficient therapeutic response based on clinical signs or worsening of symptoms after 2 weeks of treatment.
- **Death.**
- **Lost to follow-up** (Every effort must be made to contact the patient; a registered letter must be sent).
- **Non-compliance with study drug:** an indication that a patient has not agreed with or followed the instructions related to the study medication.

- **Severe Protocol violation:** an event or decision that stands in contrast to the guidelines set out by the protocol.
- **Study terminated by the Sponsor:** an indication that a clinical study was stopped by Sponsor.
- **Withdrawal of consent:** study discontinuation requested by a patient for whatever reason.
- **Other reasons,** such as administrative reasons, pregnancy, ocular trauma or surgery, inability to travel for follow-up appointments.

Before removal, each case should first be discussed with Dompé farmaceutici S.p.A.

Anyway, a subject may withdraw from the study at any time at his or her own request.

The reasons for premature discontinuation from the study will be reflected on the Study Termination Record of the eCRF. Unless the patient has withdrawn consent, the follow up visit assessments should be performed as detailed in § 6.

The investigator should advise patients that prematurely discontinue on any therapies or treatments for their condition and refer them for further treatment as appropriate

6.3.2. Discontinuation procedures

Treatment discontinuation

Patients who discontinue the treatment will not be withdrawn from the study by default, but will be asked to complete safety and efficacy observations as per the protocol, unless otherwise they withdraw their consent.

Study discontinuation

For any patient discontinuing the study following randomization, the Investigator will:

- ask the patient to undergo, as far as possible, a final medical visit (Early Termination Visit - ETV) to examine the patient's health conditions. This examination will verify that all values tested at screening have remained within a clinically acceptable range (i.e., not clinically significant changes compared to screening).
- arrange for alternative medical care of the withdrawn patient, if necessary.
- report in the eCRF date and time of the last dose administration, and date and primary reason of study discontinuation.
- record in the eCRF any follow-up if the patient is withdrawn for an AE. AE's should be followed until resolution.

6.3.3. Replacement procedure

Patients in this study who prematurely discontinue treatment will not be replaced.

It will be documented whether or not each patient completed the clinical study. If, for a patient, study treatment or observations are discontinued, the primary reason for discontinuation will be recorded.

6.4. END OF STUDY

Patients completing the double-blind treatment and follow-up (Visits 1 Baseline to Visit 7 Follow up) will be considered completers.

For the purpose of this trial, the End of Study is defined as the date of the last visit of the last patient. The Investigator and the Sponsor have the right to discontinue the study at any time for reasonable medical and/or administrative reasons. As far as possible, this should occur after mutual consultation. Reasons for discontinuation have to be documented appropriately. In this event, no further patients will receive doses of the study drugs, and patients already having received a dose of study drug will not receive any further doses of the study IMP but will undergo all safety assessments scheduled after the last dose of study drug, up to and including the end of study examination.

7. ENDPOINTS

7.1. STUDY ENDPOINTS

The study objective is to assess the efficacy and safety of cenegermin when administered as ophthalmic solution to patients with moderate to severe DED.

Evaluation of the clinical efficacy and safety during and at the end of treatment with cenegermin/placebo will be performed on the basis of the following assessments at each time point.

Evaluations will be performed on day -8 (screening), day 1+2 (visit baseline), day 14±2 (week 2), day 28±2 (week 4 End of treatment), day 56±2 (week 8 Visit 4 FU), day 84±4 (week 12 Visit 5 FU), day 112±7 (week 16 Visit 6 FU) and day 168±7 (Week 24 Visit 7 FU), according to the schedule of evaluation (§ 2)

7.1.1. Co-Primary endpoints

- Schirmer I test (without anesthesia) >10mm/5min at week 4.
- Change from baseline in Symptoms questionnaire (SANDE) global score at week 12.

7.1.2. Secondary endpoints

- Change from baseline in Schirmer I test (without anesthesia) [Time frame: week 4, 8, 12 and 16];
- Change from baseline in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) [Time frame: week 4, 8, 12 and 16];
- Change from baseline in Tear Film Break-Up Time (TFBUT) [Time frame: week 4, 8, 12 and 16];
- Change from baseline in Symptoms questionnaire (SANDE) scores for severity and frequency [Time frame: week 8, 12 and 16];
- Number of patients experienced a worsening in symptom scores (SANDE) and/or NEI score $\geq 50\%$ assessed at week 4;
- Quality of life (IDEEL) questionnaire [Time frame: week 4, 8, 12 and 16].

7.1.3. Exploratory endpoints

- Proportion and frequency of preservative free artificial tears use (n° drops/day) during the treatment period;
- Frequency of preservative free artificial tears use (n° drops/day) during the follow up period;
- Change from baseline in Schirmer I test (without anesthesia) Vs week 2;
- Change from baseline in Symptoms questionnaire (SANDE) global score [Time frame: week 2 and 4];
- Change from baseline in Symptoms questionnaire (SANDE) scores for severity and frequency [Time frame: week 2 and 4];
- Change from baseline in Cornea and conjunctiva vital staining with fluorescein (National Eye Institute [NEI] scales) Vs week 2;
- Change from baseline in Tear Film Break-Up Time (TFBUT) Vs week 2;

- Number of patients experienced a worsening in symptom scores (SANDE) and/or NEI score $\geq 50\%$ assessed at week 2;
- Change from baseline Schirmer test II (with topical Anesthesia) vs Week 4;
- Change from baseline in BCDVA.

7.1.4. Safety endpoint

- Incidence and frequency of Treatment-emergent adverse events (TEAEs), assessed throughout the study.

8. EVALUATION OF ADVERSE EVENTS AND SAFETY INFORMATION

8.1. DEFINITIONS

Adverse Event

An **Adverse Event (AE)** is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Adverse Drug Reaction

An **Adverse Drug Reaction (ADR)** is defined as any noxious and unintended response to a medicinal product related to any dose. Any responses to a medicinal product means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out.

The definition covers also medication errors and uses outside what is foreseen in the protocol, including misuse and abuse of the product. For the purposes of regulatory safety reporting, “reasonable possibility” means there are facts (evidence) or arguments to suggest a causal relationship between the drug and the adverse event. Adverse events are to be considered unrelated if the relationship to the study drug, as described in the table in § 8.3.1, is none or unlikely; whereas any AE reported in the study having a possible, probable or highly probable relationship to study drug will be considered as an ADR.

Serious Adverse Event

A **Serious Adverse Event (SAE)** is defined as any adverse experience that, in the view of either the Investigator or Sponsor, meets any of the following criteria:

- results in death,
- is life-threatening (i.e. the patient was at immediate risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it were more severe),
- requires inpatient hospitalization or prolongation of existing hospitalization.

NOTE: In general, hospitalization means that the individual remained at the hospital or emergency ward for observation and/or treatment (usually involving an overnight stay) that would not have been appropriate in the physician's office or an outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred, the event should be considered serious.

- results in persistent or significant disability/incapacity.

NOTE: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions, but do not constitute a substantial disruption.

- is a congenital anomaly/birth defect,
- is an important medical event.

NOTE: An important medical event is an event that may not result in death, be life threatening, or require hospitalization, but may be considered a SAE when, based upon appropriate medical judgment, it may jeopardize the patient's wellbeing and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions for SAEs. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in patient hospitalization or the development of drug dependency or drug abuse.

Pre-planned hospitalization or hospitalization for routine treatment or monitoring of the studied indication, not associated with any deterioration in condition are not considered to be SAEs (see Par. 8.4.2). These events must be recorded in the AE page of the eCRF where a variable will be ticked to indicate that they are not SAEs. Death shall always be reported as SAE and cause of death shall always be specified when known.

Unexpected Adverse Event/Reaction

An AE or ADR is considered unexpected if it is not listed in the Investigator Brochure or is not listed at the specificity or severity that has been observed and listed in the Investigator Brochure. Events that are mentioned in the Investigator Brochure (section Reference Safety Information) as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation are considered unexpected. The determination of expectedness is made by the Sponsor on the basis of the IB Reference Safety Information (RSI) section.

Suspected unexpected serious adverse reaction

A **suspected unexpected serious adverse reaction (SUSAR)** is defined as an adverse reaction that is both unexpected (not consistent with the applicable reference safety information) and also meets the definition of a Serious ADR.

Adverse Events (AEs) of special Interest (Sight-threatening Events)

The following adverse events are considered to be of special interest and by default shall be reported as SAEs (medically important criteria):

- AEs that caused a decrease in visual acuity of >30 ETDRS letters or > +0.6 LogMAR (compared with the last assessment of visual acuity at the last visit) lasting >1 hour
- AEs that caused a decrease in visual acuity to the level of Light Perception or worse lasting >1 hour
- AEs that required surgical intervention (e.g., conventional surgery, vitreous tap or biopsy with intravitreal injection of anti-infectives, or laser or retinal cryopexy with gas) to prevent permanent loss of sight
- AEs associated with severe intraocular inflammation (i.e., 4+ anterior chamber cell/flare or 4+ vitritis)
- AEs that, in the opinion of the Investigator, may require medical intervention to prevent permanent loss of sight.

8.2. ADVERSE EVENT (AE) MONITORING

Following study informed consent form signature, at each visit, after the patient has had the opportunity to spontaneously mention any problems, the Investigator or appropriate designee should inquire about AEs by asking the standard questions:

- “Have you had any health problems since your last study visit?”
- “Have there been any changes in the medicines you take since your last study visit?”

AEs should be reported for any clinically relevant change in concomitant condition(s) that is the result of an untoward (unfavorable and unintended) change in patient's medical conditions. Changes in any protocol-specific ocular or systemic parameter evaluated during the study are to be reviewed by the Investigator. In addition, the patient's responses to any questionnaire utilized during the study are to be reviewed by the Investigator. Any untoward (unfavorable and unintended) change in a protocol-specific parameter or questionnaire response that is clinically relevant is to be reported as an AE. These clinically relevant changes will be reported regardless of causality.

All AEs should be followed-up to determine outcome of the reaction.

In order to collect as complete as possible information in the clinical study database, all ADRs and SAEs ongoing at the time the subject's study participation ends should be evaluated within 10 days after the final visit. After this period, all unresolved ADRs and SAEs will be reported as “ongoing” in the eCRF.

8.3. RECORDING

AE data should be obtained through observation of the patient, from any information volunteered by the patient, and through patient questioning.

Adverse Events:

All AEs (non-serious and serious) that occur during the course of the study will be recorded in the eCRF. Any pre-existing medical conditions or signs/symptoms present in a patient prior to the start of the study (i.e., before informed consent is signed) should be specified in the dedicated eCRF sections. Subsequent to signing an informed consent form, all untoward medical occurrences that occur during the course of the study must be documented on eCRF. AEs will be collected till last Follow Up visit (week 24).

When possible, signs and symptoms indicating a common underlying pathology should be documented as one comprehensive event. For each recorded event, the AE documentation must include the onset date, outcome, resolution date (if event is resolved), intensity (i.e., severity), any action with study treatment taken as a result of the event, and an assessment of the adverse event relationship to the study treatment.

Serious Adverse Events:

The Investigator must record all SAEs, including sight-threatening events, occurring at any time during the study (after signature of the informed consent) regardless of presumed causal relationship, on the Serious Adverse Event form in the eCRF of the EDC system within 24 hours of learning of the event; information on the SAE must also be recorded on a specific Non-Carbon Repeat SAE form (included in the Investigator's Site File).

8.3.1. Relationship of AEs to the Investigational Product

The Investigator will assess the relationship between the AE and the investigational medication, according to the criteria in **Table** below:

Relationship of the Adverse Event to the IMP

None (Intercurrent Event)	An event that is not and cannot be related to the Investigational Product, e.g. patient is a passenger in a road traffic accident or surgical intervention performed during the study, but planned before patient enrolment into the study
Unlikely (remote)	Relationship is not likely e.g. a clinical event including laboratory test abnormality with temporal relationship to drug administration which makes a causal relationship improbable and in which other drugs, chemicals or underlying disease provide more plausible explanations
Possible	Relationship may exist, but could have been produced by the patient's condition or treatment or other cause
Probable	Relationship is likely, the AE abates upon discontinuation of Investigational Product and cannot be due to the patient's condition
Highly Probable	Strong relationship, the event abates upon discontinuation of Investigational Product and, if applicable, re-appears upon repeat exposure

An ADR is defined as an adverse experience which is reasonably likely to have been caused by the drug. Events considered "Possible", "Probable" and "Highly Probable" related to the IMP treatment and implying a reasonable possibility, if considered unexpected, will be reported to appropriate regulatory authorities by the Sponsor.

8.3.2. Severity of AEs

The Investigator will grade the severity of any AE using the definitions in the Table below. For each episode, the highest severity grade attained should be reported.

Severity of the Adverse Event

Mild	Grade 1 - Does not interfere with patient's usual function (awareness of symptoms or signs, but easily tolerated [acceptable]).
Moderate	Grade 2 - Interferes to some extent with patient's usual function (enough discomfort to interfere with usual activity [disturbing]).
Severe	Grade 3 - Interferes significantly with patient's usual function (incapacity to work or to do usual activities [unacceptable])

8.4. SERIOUS ADVERSE EVENT REPORTING

8.4.1. Reporting Procedure for Investigators to Dompé and CRO

The Investigator must report all SAEs filling in and signing a SAE Report form, including sight threatening events, regardless of presumed causal relationship, to Dompé Pharmacovigilance, Safety and Surveillance Dept and **CCI** Pharmacovigilance, by e-mail (preferred) or fax immediately, anyway **within 24 hours** of learning of the event. Contact details for SAE reporting are provided below:

PPD

[Redacted contact details for PPD]

Respective IRB must also be informed of all SAEs according to local specific requirements.

If assistance is needed with the reporting of a SAE, **CCI** may be contacted at the addressed provided above.

SAEs will be managed directly by the Dompé Pharmacovigilance, Safety and Surveillance department, with **CCI** support for follow-up requests.

The investigator should also report information on SAEs that continue after patient has completed his/her participation in the study (whether study completion or withdrawal), unless patient has withdrawn his/her consent.

Follow-up reports (as many as required) should be completed and faxed/e-mailed following the same procedure above, marking the SAE form as “follow up Number XX”.

Whenever more than one SAE is observed, the Investigator should identify which is the primary adverse event, i.e. the most relevant one. If other events are listed in the same report, the Investigator, along with their relatedness to the IMP, should identify which AEs are serious and which are non-serious. In any case, the Investigator is requested to record his/her opinion about the relatedness of the observed event(s) with the IMP.

An assessment of expectedness and causality of each SAE will be performed case by case by Dompé Pharmacovigilance. For SAE reported by the Investigator as not related that is subsequently assessed to be related by Dompé, the Investigator will receive a notification. Depending on the nature and seriousness of the AE, further information, including copies of appropriate medical records of the patient, as well as results of laboratory tests performed will need to be included in the patients chart. If the patient was hospitalized, a copy of the discharge summary should be available, if possible.

In line with CT3 Detailed Guidance and ICH E2A provisions, although the Investigator does not usually need to actively monitor patients for AEs once the trial has ended, if the Investigator becomes aware of a SAE occurring to a patient after that patient has ended his/her participation in the study (whether study completion or withdrawal), the SAE should be reported by the Investigator to the Dompé Pharmacovigilance. Such “post-study cases” should be regarded for expedited reporting purposes as though they were study reports. Therefore, a causality assessment and determination of expectedness are needed for a decision on whether or not expedited reporting is required.

8.4.2. Conditions that should not be reported as serious adverse events

The conditions listed below, that may require hospitalization of a patient, are not considered to be SAE and shall not be reported as such, but only need to be recorded in the eCRF:

- Hospitalizations planned before entry into the clinical study which is part of the normal treatment or monitoring of the studied indication and not associated with any deterioration in condition.
- Hospitalization for routine treatment or monitoring of the studied indication, not associated with any deterioration in condition.
- Hospitalization for treatments, which was elective or pre-planned, for a pre-existing condition that is unrelated to the indication under study and did not worsen.
- Hospitalization for general care not associated with any deterioration in condition.
- Treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of SAEs given above and not resulting in hospital admission.

In addition, the following situation shall not be considered SAE:

- Abnormal test results that do not induce clinical signs and/or symptoms and require intervention/therapy, i.e. are not clinically significant.

8.4.3. Reporting Procedure to the IEC/IRB and to Regulatory Authorities

In addition to reporting the SAE to Dompé and CRO, the Investigator must also comply with the requirements related to the reporting of SAEs to the IEC/IRB which approved the study. The requirements of IRBs vary from one IRB to another; however, as a minimum requirement, the Investigators must promptly report all SUSAR to their IRB.

SUSARs shall be reported by Dompé as defined in this section, in line with applicable US and EU requirements, as soon as possible, but in no case later than:

- seven calendar days after becoming aware of the information if the event is fatal or life threatening; to be followed by any relevant information within eight days.
- fifteen calendar days after becoming aware of the information if the event is serious but neither fatal nor life threatening.

Treatment will be unblinded by Dompé Drug Safety Pharmacovigilance prior to submission of a SUSAR to Regulatory Authorities and only cases referred to active treatment will be considered expeditable for regulatory reporting, in line with law requirements.

If the results of an investigation show that an ADR not initially determined to be reportable is reclassified as reportable, the Sponsor shall report such reaction in a written safety report as soon as possible, but in no event later than 7/15 calendar days after the determination is made.

In line with provisions set forth in 21CFR312, Dompé shall notify FDA and all participating US Investigators in an IND safety report of any SUSAR and of potential serious risks, from clinical trials or any other source.

The Investigators in turn shall notify their IRB.

According to US regulations, the Investigators will be informed in an unblinded fashion: Dompé will open the blind and report only SUSAR referred to Oxervate[®] (cenegermin) ophthalmic solution.

Copies of all correspondence relating to reporting of any SAEs to the IRB should be maintained in the Investigator's Files.

Dompé shall also notify FDA in an IND safety report of potential serious risks, from clinical trials or any other source, as soon as possible after Dompé determines that the information qualifies for reporting, in particular shall notify of:

- any suspected adverse reaction that is both serious and unexpected. Dompé must report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event.
- findings from other studies that suggest a significant risk in humans exposed to the drug. Such a finding would result in a safety-related change in the overall conduct of the clinical investigation.
- findings from animal or in vitro testing that suggest a significant risk in humans exposed to the drug
- increased rate of occurrence of serious suspected adverse reactions.

Dompé shall report SUSAR to the Regulatory Authorities in the EU and to ECs, as per applicable requirements, within 7/15 calendar days.

EU Investigators shall be informed periodically, in a blinded fashion, in line with applicable requirements.

8.4.4. Periodical Reporting to Regulatory Authorities

Dompé shall be responsible to prepare and submit annual safety reports (Development Safety Update Report – DSUR) to relevant Regulatory Authorities.

8.5. UNMASKING OF THE STUDY TREATMENT

Masked information on the identity of the assigned investigational product will be provided for each patient. Unblinding can only occur in case of emergency, when knowledge of the treatment identity is essential for treating the subject. If the treatment code needs to be broken in the interest of patient safety for a medical emergency, the Investigator is allowed to break the treatment code for the specific patient, even before informing the Sponsor. The Investigator must always notify the Sponsor, so that the reason for any premature unmasking can be documented, by means of a communication to CRO/Dompé Pharmacovigilance, Safety and Surveillance to the contact details in the section “Contact Information” and to Dompé Medical Expert. The Investigator will inform the Dompé representative (Dompé Medical Expert) if an emergency unmasking was performed without revealing the treatment identity, in order to avoid a dissemination of unmasked information.

Additionally, Dompé Pharmacovigilance, Safety and Surveillance shall unmask the patient’s treatment if a reported SAE meets criteria of a Suspected Unexpected Serious Adverse Reaction (SUSAR) in order to fulfil expedited regulatory reporting requirements. Unmasked information shall not be disclosed to Investigators.

The identity of the treatments will remain unknown to the patient, Investigator, site staff and Dompé’s clinical research personnel and **CCI** (apart from pharmacovigilance).

8.6. FOLLOW-UP OF PATIENTS WITH ADVERSE EVENTS (AES)

The Investigator is responsible for adequate and safe medical care of patients during the trial and for ensuring that appropriate medical care and relevant follow-up procedures are maintained after the trial. All AEs should be followed-up to determine outcome of the reaction or until 10 days after the final visit. The Investigator should follow-up the event until resolution or stabilization of the condition. It is the Investigator's responsibility to assure that the patients experiencing AEs receive definite treatment for any AE, if required.

If patient was hospitalized due to a SAE, a copy of the discharge summary is to be forwarded to **CCI** as soon as it becomes available. In addition, a letter from the Investigator that summarizes the events related to the case as well as results of any relevant laboratory tests also may be requested. Further, depending upon the nature of the SAE, Dompé may request copies of applicable segments of the patient’s medical records.

For pharmacovigilance purposes, all SAEs should be followed-up in order to elucidate as completely and practically as possible their nature and/or causality until resolution of all queries, clinical recovery is complete, laboratory results have returned to normal, stable condition is reached or the subject is lost to follow-up. Follow-up may therefore continue until after the subject has left the study up to 10 days after his/her discontinuation from the study for unrelated SAEs, and without timelines for related SAEs, unless the patient denies consent.

8.7. PREGNANCY IN THE CLINICAL TRIAL

Women of childbearing potential are not excluded from the study as long as adequate birth control methods are being utilized. Women of childbearing potential are defined as all women physiologically capable of becoming pregnant. Adequate birth control methods are summarized in the protocol's exclusion criteria.

Prior to enrollment in the clinical trial, female patients of childbearing potential and their partners must be advised of the importance of avoiding pregnancy during the entire course of the study treatment and for the 30 days after the study treatment period ends and of the potential risks associated with an unintentional pregnancy. During the trial (during the study treatment period and during the follow up), female patients are to be instructed to contact the Investigator immediately if they suspect they might be pregnant; in the same way, male patients who become aware that the partner might be pregnant, are to be instructed to contact the Investigator immediately.

The Investigator must report every pregnancy on a pregnancy report form as soon as possible (within 24 hours of learning of the pregnancy) to CCI [REDACTED] Pharmacovigilance, Safety and Surveillance contacts reported at Paragraph 8.4.1, even if no AE has occurred, and follow it to term.

The pregnancy form will be utilized to capture all pregnancy-related information until the birth of the child for both the patient and the partner.

If the pregnancy is associated with a SAE (e.g. if the mother is hospitalized for dehydration), in addition to the pregnancy report form, a separate SAE report form must be filed as described in § 8.4 with the appropriate serious criterion (e.g. hospitalization) indicated on the SAE report form. Miscarriage, stillbirth and any malformation/disease must be reported as a SAE. Any pregnancy leads to the immediate cessation of the study treatment.

8.8. ADVERSE EVENTS CAUSING TREATMENT DISCONTINUATION

If a patient is withdrawn from the study as a consequence of an AE, this must be recorded and reasoned in the eCRF, and the patient must be followed up until the resolution of the AE or as instructed by the medical monitor.

8.9. OVERDOSE

Overdose (accidental or intentional) which may or may not result in serious adverse reactions, shall be reported to Sponsor Drug Pharmacovigilance, Safety and Surveillance CCI [REDACTED] by email or fax, following the same procedure for SAE, within 24 hours from the Investigator's knowledge of its occurrence. This includes reports related to drug intake through different routes (e.g. ingestion) or with suicidal intentions and consequent drug overdose.

An overdose of Oxervate® 20 mcg/mL of cenegeermin ophthalmic solution is defined as the administration of 50% or more additional drops on any given treatment day.

The Investigator shall provide in the SAE form information about symptoms, corrective treatment and outcome of overdose. The Medical Expert should be contacted to discuss corrective treatment, if necessary.

9. STATISTICS

9.1. SAMPLE SIZE

The sample size of the study is calculated based on results from previous studies.

Considering a randomization ratio 1:1 and a one-sided alpha of 0.025, a total of 72 evaluable patients will allow to achieve an overall power of >90% to show superiority of cenegermin 20 mcg/mL ophthalmic solution vs. vehicle in terms of the co-primary endpoints, expecting a difference of 42% in Schirmer I rate of responders in favour of cenegermin 20 mcg/mL ophthalmic solution treatment at Week 4 and a >10-point improvement from baseline in global SANDE score at week 12 (with a SD of 12 points). The Δ in SANDE global score of 10 points is based on literature. According to the literature, addition of a topical steroidal anti-inflammatory drug to the treatment regimen of Sjogren's patients who are already on cyclosporine therapy may expect to see an improvement in symptoms of about 13-14 points.²⁵ Since NGF is not a steroidal anti-inflammatory, the expected improvement in symptoms is likely to be significantly lower than 13-14 points. However, to maintain an ambitious and clinically-relevant goal, we set the Δ for SANDE at 10 points. The assumption for SD was set at 12 based on the variability in symptom scores among Sjogren's patients who have been on topical cyclosporine therapy.²⁶

Since both endpoints must be met in order to claim superiority of cenegermin 20 mcg/mL ophthalmic solution vs. vehicle, no multiplicity correction of alpha is required. Assuming that 10% of subjects will not be evaluable for primary analysis, a total of approximately 80 subjects is expected to be enrolled.

9.2. ANALYSIS POPULATION

The following population will be defined:

- The Safety (SAF) population will consist of all randomized patients who received at least one dose of the investigational product. Safety population will be analyzed according to the actual treatment received. The SAF population will be used to present results on safety data.
- The Full Analysis Set (FAS) population will consist of all randomized patients who received at least one dose of the investigational product. FAS population will be analyzed according to ITT principle, i.e. by treatment allocation. The FAS population will be used for the primary analyses of the study and to present results on efficacy data.
- The Per Protocol (PP) population will consist of all randomized patients who received at least one dose of the investigational product and do not have Major Protocol Deviations. The PP population will be used for sensitivity analyses.

9.3. OVERVIEW OF PLANNED STATISTICAL ANALYSES

The study plans for the following statistical analyses:

- Final analysis: this analysis will be conducted when all randomized subjects have completed the treatment at week 4 and FU at week 12. After data up to week 12 have been locked, results will be provided in an aggregate way without unblinding patients, investigators and study personnel about treatment codes.
- Addendum to final analysis: this additional analysis will be conducted when all randomized subjects have completed the FU at week 24, and the study database has been locked and unblinded. A dedicated addendum to the CSR will be created.

9.4. STATISTICAL METHODOLOGY

9.4.1. General Considerations

Appropriate descriptive statistics will be produced by treatment arms according to the nature of the variable. For continuous data, number of observations, mean, standard deviation, median and range (minimum and maximum) will be presented. For qualitative data, frequency distributions and percentages per category will be presented. If appropriate, confidence intervals around the mean or the proportions will be presented. The number of subjects with missing data will be presented under the “Missing” category. Missing values will not be included in the denominator count when computing percentages. When continuous data will be summarized, only the non-missing values will be evaluated for computing summary statistics. Any exception will be declared.

For the purpose of efficacy analysis in this trial, the statistical analysis (both descriptive and inferential) of some endpoints will be done on the eligible eye when applicable. Details will be provided in the statistical analysis outputs as notes.

Unless otherwise specified, the significance level used for statistical testing will be 0.05 and two-sided tests will be used. All patient data collected on the CRF will be listed by patient and centre.

The Statistical Analysis Plan will be issued before database lock with more technical and detailed elaboration of the principal features of statistical analyses. Additional post-hoc analysis may be produced to further allow comparison between treatment and control, according to the results obtained. Any deviations from the original statistical plan (including unplanned analyses) will be documented in the Clinical Study Report.

9.4.2. Primary Estimand

A Treatment Policy Estimand for signs is defined by the following:

- Population: Adult patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A, as defined by the inclusion-exclusion criteria of the study;
- Variable: Schirmer I test at week 4;
- Intercurrent event: The occurrence of an intercurrent event is irrelevant. All observed values will be used regardless of occurrence of an intercurrent event. Retrieved drop-outs will be used for data imputation of missing data;

- Population-level summary: Difference in proportion of patients reaching a value of Schirmer I test (without anesthesia) >10mm/5min at week 4.

A Treatment Policy Estimand for symptoms is defined by the following:

- Population: Adult patients with severe Sjogren's dry eye disease under treatment with Cyclosporine A, as defined by the inclusion-exclusion criteria of the study;
- Variable: SANDE global score at week 12;
- Intercurrent event: The occurrence of an intercurrent event is irrelevant. All observed values will be used regardless of occurrence of an intercurrent event. Retrieved drop-outs will be used for data imputation of missing data;
- Population-level summary: Difference in means of change from baseline in the global SANDE score at week 12.

9.4.3. Analysis of efficacy variables

9.4.3.1. Primary analyses

The following null hypothesis is defined on the first primary endpoint: the proportion of patients reaching a value of Schirmer I test (without anesthesia) >10mm/5min at week 4 in cenegermin (rhNGF) is lower or equal than control:

$$H_{01}: T_{\text{rhNGF}} \leq T_{\text{CONTROL}}$$

$$H_{11}: T_{\text{rhNGF}} > T_{\text{CONTROL}}$$

where T_{rhNGF} and T_{CONTROL} are the proportion of patients reaching a value of Schirmer I test (without anesthesia) >10mm/5min at week 4 for cenegermin and control groups, respectively. The null hypothesis H_{01} will be rejected if the associated primary analysis p-value will be lower than 0.025.

This primary endpoint will be analyzed by means of a logistic regression adjusting by pre-defined baseline factors (site, gender, age class, baseline Schirmer I test value) and a one-sided test will be used to test for differences between treatment groups.

Similarly, the following null hypothesis is defined on the co-primary endpoint: the change from baseline in the global SANDE score at week 12 in cenegermin is lower or equal than control:

$$H_{02}: \mu_{\text{rhNGF}} \leq \mu_{\text{CONTROL}}$$

$$H_{12}: \mu_{\text{rhNGF}} > \mu_{\text{CONTROL}}$$

where μ_{rhNGF} and μ_{CONTROL} are the change from baseline in the global SANDE score at week 12 for cenegermin and control groups, respectively. The null hypothesis H_{02} will be rejected if the associated primary analysis p-value will be lower than 0.025.

This co-primary endpoint will be analyzed by means of an ANCOVA model adjusting by pre-defined baseline factors (site, gender, age class, baseline global SANDE score) and a one-sided test will be used to test for differences between treatment groups.

Both null hypotheses H_{01} and H_{02} must be rejected in order to claim superiority of cenegermin over control. Consequently, no multiplicity correction of type I error will be applied on primary endpoints analysis.

Since patients who discontinue the treatment with the IMP will not be withdrawn from the study but will be asked to complete safety and efficacy assessments as per the protocol, missing data under treatment policy strategy will be addressed by modeling patients with missing data after retrieved drop-outs (based on assumption of missing data would have been like retrieved drop-outs if they were assessed). Retrieved drop-out patients are defined as patients who discontinue study treatment and decide to remain in the study by following the schedule of assessments and continuing to adhere to protocol requirements.

If enough retrieved drop-out data are available to allow convergence of a regression model, a Multiple Imputation model based on retrieved drop-outs (MI-RD) will be used for analysis. Specifically, MI will be performed based on the subjects' allocated treatment arm and observed values (baseline and intermediate) as covariates in a regression model using data from subjects that discontinued the treatment but have the primary endpoint measurement with gender, and age class as covariates. MI-RD will be implemented into different steps:

- Intermittent missing data up to primary time point will be imputed using MCMC methods assuming missing at random (MAR) data;
- The remaining missing values with a monotone missing data pattern will be imputed based on observed data of retrieve dropouts;
- the fully imputed datasets will be analyzed and results will be combined using Rubin's to draw inference.

If not enough data will be retrieved after study treatment discontinuation for assure the convergence of the MI-RD regression model (the final decision will be done at the time of the analysis and reported in the CSR; different approaches might be used for the two co-primary endpoints), the same model will be fit using data from subjects of control group, washing-out the effect of treatment; this approach does not assume benefits for cenegermin in case of discontinuation and limits a post-discontinuation clinical effect to that of vehicle. Specifically, wash-out approach will be implemented in this way:

- Intermittent missing data up to primary time point (week 4 for Schirmer I and week 12 for SANDE) will be imputed using MCMC methods assuming MAR;
- The remaining missing values in the vehicle group with a monotone missing data pattern will be imputed based on observed data of the control patients with available endpoint, while the remaining missing values in the treatment group with a monotone missing data pattern will be imputed based on observed and imputed data of the control patients;
- All imputed data will be pooled and analyzed, and results will be combined using Rubin's to draw inference.

Whether for MI-RD or wash-out approach, the adjusted estimated treatment difference between cenegermin and vehicle (difference in proportions for Schirmer's test and differences in means for SANDE) will be displayed together with the corresponding two-side 95% confidence interval and p-value.

9.4.3.2. Sensitivity analyses

The following sensitivity analyses are defined to assess the robustness of results on each primary endpoint versus assumptions used in the statistical model for the main estimators:

- The comparison between treatment and control will be performed in the FAS population by means of MI under MAR assumption instead of missing not at random (MNAR). MI will be implemented in two steps:
 - Intermittent missing data up to primary time point (week 4 for Schirmer I test and week 12 for SANDE) will be imputed using MCMC methods assuming MAR. A separate imputation model will be used for each treatment arm. The imputation models will include the observed values (baseline and intermediate), gender, and age class as covariates. In case of non-convergence or non-estimability issues, a single model will be considered with treatment arm added as explanatory variable to the model;
 - The remaining missing values with a monotone missing data pattern will be imputed based on data of corresponding treatment group.

Each imputed dataset will be analyzed using observed and imputed as described in section 9.4.3.1. Rubin's rule will be used for combining results to draw inference. The adjusted estimated treatment differences between cenegermin and vehicle (difference in proportions for Schirmer I test and differences in means for SANDE) will be displayed together with the corresponding two-side 95% confidence intervals and p-values.

- A tipping point strategy will be used as a sensitivity analysis for missing data for assessment of superiority (if shown) of cenegermin. Tipping point will assess how departures from MI under MNAR assumptions must be in order to overturn conclusions from the primary superiority analysis. Tipping point will be based on iterative application of MI-RD (or MI under wash-out approach), where the imputed values for the cenegermin arm are shifted at a constant Δ to represent a worse effect in each iteration. The tipping points are the smallest Δ s at which no statistical significance is shown ($p \geq 0.025$).

In addition, for each co-primary endpoint, the regression models detailed in section 9.4.3.1 will be performed for supportive purposes:

- by considering complete cases only (i.e. without considering patients with missing primary endpoint);
- on the PP set instead of FAS.

Details on sensitivity and supportive analyses will be provided in the SAP.

9.4.3.3. Secondary analyses

In case analysis of the co-primary endpoints leads to rejection of null hypothesis, the following key secondary endpoints will be tested in a conditional sequential manner to show superiority of cenegermin versus control (at alpha one-sided 0.025) according to the following ranking:

1. Proportion of patients reaching a value of Schirmer I test (without anesthesia) $> 10\text{mm}/5\text{min}$ at week 8;

2. Change from baseline in SANDE scores for severity at week 12;
3. Change from baseline in SANDE scores for frequency at week 12;
4. IDEEL modules (Quality of Life [27 questions], Dry eye Treatment satisfaction & Bother [10 questions], and Dry eye Symptom bother [20 questions]) at week 12 and at week 4 (in this order);
5. Change from baseline in Cornea and conjunctiva vital staining with fluorescein NEI scales at week 4, week 8 and at week 12 (in this order);
6. Change from baseline in TFBUT at week 4, week 8 and at week 12 (in this order).

This hierarchical test strategy protects the family-wise false positive error rate at the overall one-sided 0.025 level.

Key secondary endpoint #1, will be analyzed as detailed in section 9.4.3.1.

Key secondary endpoints #2 - #6 will be analyzed by means of an ANCOVA model adjusting by pre-defined baseline factors (site, gender, age class, corresponding baseline value). Missing data will be imputed according to MI-RD (or wash-out approach, see section 9.4.3.1).

In case of not rejection of null hypothesis, the above test strategy will not be performed. Instead, independently of results on primary endpoint, descriptive in nature analyses will be performed on all secondary endpoints at each available timepoints by means of descriptive statistics and by appropriate parametric tests depending on the nature of the variable and its distribution.

Data transformation might be used in order to satisfy the assumption of normality requested by parametric statistical tests. In case such assumptions are not met, non-parametric counterpart tests will be used. Change from baseline value (for continuous variables) and shift tables versus baseline (for categorical variables) will also be summarized for all post-baseline visits.

Further details will be provided in the SAP.

9.4.4. Analysis of exploratory variables

In addition to descriptive statistics at each available time point, explorative variables will be analyzed by means of inferential tests depending on their nature and distribution (all confidence intervals and statistical tests on explorative endpoints are of descriptive nature). Change from baseline value (for continuous variables) and shift tables versus baseline (for categorical variables) might be reported for all post-baseline visits.

Correlation between sign and symptom scores at different time points will be assessed.

9.4.5. Analysis of safety variables

Adverse events (AEs) will be coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA).

Treatment-emergent AEs (TEAEs) are all events occurring or worsening after the first dose of the IMP. TEAEs will be presented by treatment arm in terms of number of AEs and their incidence by System Organ Class

(SOC) and Preferred Terms (PT) using MedDRA. Analyses will be provided also by seriousness, relationship to treatment, severity and study period (treatment or follow-up).

Individual AEs will be listed in patient data listings.

9.4.6. Subgroup analysis

Subgroup analyses of primary and secondary endpoints will be performed on the following subgroups of baseline characteristics:

- Age class (\leq Median, $>$ Median),
- Race,
- Gender,
- Ethnicity,
- Sjögren's syndrome (primary, secondary).

Statistical details and potential new subgroups definitions will be reported in the SAP.

9.4.7. Missing data

All reasonable efforts will be made to reduce the rate of missing data. Investigators will be trained about the importance of patient retention and full data capture. Also, any reasonable attempts should be made by the Investigators to emphasize continued subject's participation for the full duration of the trial. However, in order to minimize missing data, if a patient cannot refer to the site for a planned follow-up visit, the Investigator will try to obtain any relevant information from the patients, including documents/laboratory results available from local medical care.

10. ETHICAL CONSIDERATIONS

10.1. INSTITUTIONAL REVIEW BOARD AND INDEPENDENT ETHICS COMMITTEE

United States

Approval by the Institutional Review Board (IRB) before the start of the study will be the responsibility of the Principal Investigator (PI). A copy of the approval letter will be supplied to the Sponsor, along with a roster of IRB members or the US Department of Health and Human Services (DHHS) general assurance number. During the course of the study, the PI will provide timely and accurate reports to the IRB on the progress of the study, at intervals not exceeding 1 year (or as appropriate), and will notify the IRB of serious adverse events (SAEs) or other significant safety findings. The study protocol, informed consent form (ICF), information sheet advertisements, and amendments (if any) will be approved by the IRBs at the study centers in conformance with Code of Federal Regulations (CFR), Title 21, Part 56.

Europe

This study will be carried out in full compliance with the guidelines of the independent ethics committee (IEC) and government agencies of each respective country as well as the European Union (EU) Clinical Trial Directive (Directive 2001/20/EC), where applicable. Before the study begins, the Sponsor will require approval from an IEC and Regulatory agency. During the course of the study, the Sponsor or authorized contract research organization (CRO) representative will provide timely and accurate reports to the IEC on the progress of the study, at intervals not exceeding 1 year (or as appropriate), and will notify the IEC of SUSARs or other significant safety findings. The study protocol, ICF, information sheet advertisements, and amendments (if any) will be approved by the EC at the study centers in conformance with the EU Clinical trial directive (Directive 2001/20/EC), and local regulations.

10.2. ETHICAL CONDUCT OF THE STUDY

The study will be conducted in full compliance with applicable legislation, FDA, EMA and ICH guidelines for good clinical practice (GCP) and in accordance with the ethical principles that have their origins in the Declaration of Helsinki and 21 CFR § 312.120.

10.3. DATA MONITORING COMMITTEE

A Data Monitoring Committee is not required for this trial considering the following point:

- The drug under investigation is well characterized and known for not harming patients
- The study design is not complex and already performed in other clinical trial in DED
- The study does not have a long duration.

10.4. PATIENT INFORMATION AND CONSENT

Eligible patients can take part in the study only after providing the written informed consent approved by the IEC/IRB. Informed consent must be obtained before starting any procedure pertaining to the study (i.e. all the procedures described in the protocol). A Patient Information Sheet and Informed Consent Form, which meet regulatory requirements and are appropriate for this study, will be provided to the patient.

Each patient will read or be read (if he or she cannot read or write), assent understanding of, and sign or thumbprint an instrument of informed consent and after having had an opportunity to discuss them with the PI before signing; each patient will be made aware that he or she may withdraw from the study at any time.

The informed consent statement contains all the elements of informed consent and contains all the core elements and mandatory statements as defined in the CFR. Signed copies of the ICF and Patient Information Sheet will be given to the patient, and both documents will be placed in the Investigator's site files. A unique patient identification (PID) number will be assigned according to § 4.3 of the protocol at the time the patient signs the ICF.

10.5. CONFIDENTIALITY

All information obtained during the conduct of the study will be regarded as confidential. An agreement for disclosure will be obtained in writing by the patient and will be included in the ICF. Patient's data collected during the study will be handled in accordance with applicable data protection laws and regulations.

On the CRFs, or Diary, patients will be identified ONLY by the assigned patient number. If patient names are included on copies of documents submitted to Dompé farmaceutici s.p.a. or CRO, the names will be obliterated or masked and the assigned patient number added to the document.

The Investigator should keep a separate log (Patient Master List) of patient's codes, names and addresses.

10.6. COMPENSATION FOR MEDICINE-INDUCED INJURY AND INDEMNIFICATION

Before the trial formally starts, Dompé will take out a study-specific insurance contract according to national laws for patients/Investigators/Institutions participating in the clinical trial.

In case of questions about medical care, cost for medical care or insurance, patients can talk to their Investigator. Contact details will be given in the Patient Informed Consent Document.

11. DATA HANDLING AND RECORD KEEPING

11.1. CASE REPORT FORMS

All data relating to the study will be recorded on eCRFs to be provided by the CRO, through the EDC system. eCRF data are the sole property of Dompé and should not be made available in any form to third parties, except for authorized Dompé' designee or representatives of appropriate Health/Regulatory Authorities, without written permission from Dompé.

A eCRF is required and should be completed for each patient that signed the informed consent, including the screening failures. Source documents should be available to support all the data recorded in the eCRF; location of source documents, including those for which the eCRF might be accepted as being the sole source document, will be specified and listed at the center Initiation Visit.

The eCRF must be available for review to designated Dompé's representatives at each scheduled monitoring/audit visit. The PI is responsible for verifying that all data entries in the eCRFs are accurate and correct. The PI must sign the completed eCRF before database lock and its submission to the Sponsor.


Patient's diary

The patient will report in the Diary the details of self-administration at home of the IMP, as well as any new or changes in concomitant medications, any unusual medical conditions and the use of artificial tears. It is responsibility of the Investigator to explain to each patient how to enter the data in the Diary and to check the data inserted in the Diary to ensure correct completion as well as correct administration of the IMP.

The information collected in the Diary will be part of the patient's data collected.

Data reported on Diary is the sole property of Dompé and should not be made available in any form to third parties, except for authorized Dompé designee or representatives of appropriate Health/Regulatory Authorities, without written permission from Dompé.

11.2. DATA MANAGEMENT

Main Data Management activities and procedures will be accurately described in the DMP, created by  and approved by Dompé.

Data collection will involve the use of an EDC system, to which only authorized personnel will have access. In addition to periodic monitoring occurring within the system by Sponsor/CRO Monitors, programmatic edit checks will be used to review the data for completeness, logic, and adherence to study protocol (following the Data Validation Plan). As a result of this monitoring and these checks, queries may be electronically issued to the study centers and electronically closed by those study centers. The identifying information (assigned username, date, and time) for both the originator of the query (if created during the monitoring process) and the originator of the data change (if applicable), as well as the PI's approval of all changes performed on his

or her patients' data, will be collected. Reconciliation of study data and SAEs between Clinical and Drug Safety database will be performed by **CC** in ongoing basis and before the database lock. Procedure will be detailed in the DMP.

Encoding of specific data will be carried out by **CC**. For this trial, Medical History, Adverse Events and Concomitant Medication will be coded; Medical Dictionary for Regulatory Activities (MedDRA) and World Health Organisation (WHO)-DRUG Enhanced dictionaries will be used, version number of each dictionary will be documented in the DMP. Dictionary version numbers will not be changed during the study.

All data collected in the context of this study will be stored and evaluated per regulatory requirements and applicable guidances for electronic records. Also, data will be stored and evaluated in such a way as to guarantee patient confidentiality in accordance with the legal stipulations applying to confidentiality of data. Study records (e.g., copies of eCRFs, regulatory documents) will be retained at the study center, along with adequate source documentation, according to CA and ICH requirements. All study records must be available for audit by Dompé farmaceutici S.p.A.; its authorized representatives; and Regulatory Inspection by Regulatory Authority.

The investigator/institution should maintain adequate and accurate source documents and trial records that include all pertinent observations on each of the site's trial subjects. Source data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary via an audit trail.

11.3. DOCUMENTATION REQUIRED PRIOR TO INITIATION OF AND DURING THE STUDY

The following documents will be required from the Investigator prior to the initiation visit:

- Current, signed and dated Curriculum Vitae of Principal Investigator and any Sub-Investigators/co-workers. Updates should be provided at least every two years.
- A signed page of the final protocol and any amendments.
- A signed copy of the study Financial Agreement/Clinical Study Agreement with the CRO, including all study specific costs.
- List and any updates of delegated responsibility (Study Team Signature List / Delegation of Responsibilities form).
- A financial disclosure agreement completed and signed by the PI and all Sub-Investigators listed on Form FDA 1572. If applicable, the PI will provide an updated financial disclosure agreement to the Sponsor 1 year after the completion of the study.

11.4. ESSENTIAL DOCUMENT RETENTION

The Investigator will retain copies of all the essential documents (as defined by ICH-GCP E6 R2) until at least 2 years after the last approval of a marketing application in an ICH region, and until there are no pending or contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the formal discontinuation of clinical development of the Investigational Product. These documents should be retained for a longer period however if required by the applicable regulatory requirements. The Investigator should take measures to prevent accidental or premature destruction of these documents.

The essential documents include at least: the signed protocol, copies of the completed eCRFs, signed Patient Informed Consent Forms from all patients who consented, hospital records and other source documents, and all other documentation included in the Investigator Site File and Pharmacy/Dispensing File.

The Investigator will inform the CRO of the storage location of these essential documents and must contact the Sponsor before disposing of any. If the Investigator wishes to assign the files to someone else or to remove them to another location, he/she should consult with the Sponsor. about this change.

Dompé farmaceutici S.p.A. will inform the Investigator in writing when these documents no longer need to be retained.

12. STUDY MANAGEMENT

The study will be performed in accordance with the protocol, the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and ICH Harmonised Tripartite Guideline for Good Clinical Practice (ICH-GCP E6-R2) and any local regulations.

12.1. REGULATORY BODY APPROVAL

Dompé or the CRO or other consultant appointed by Dompé will obtain the necessary approval from the Regulatory Authorities/Competent Authorities/FDA, as needed, prior to initiation of the study. The study will not be started until written approval from the relevant Competent Authorities/FDA (or no objection within the timeframe set by the local regulation, as applicable) has been received by Dompé.

Where appropriate, any amendments to the Protocol will be sent to the Competent Authority/FDA.

12.2. MONITORING

Before any patient enters the study, a representative of Sponsor/CRO, will meet with the PI and his or her staff to review the procedures to be followed during the study and to train them on recording the data in the eCRFs using the electronic data capture (EDC) system. After the first patient is enrolled, the progress of the study will be periodically monitored by the Sponsor representative, a monitor, conducting on-site visits. This CRA will also be able to review query statuses remotely, possibly warranting more frequent communication with the PI and his or her staff. The PI will make available to the CRA the eCRFs, source documents, signed consent forms, and all other study-related documents. The PI and his or her staff will be responsible for reviewing eCRFs, resolving data queries generated by the CRA via the system, providing missing or corrected data, approving all changes performed on his or her data, and endorsing the patient data within the EDC system. This approval method will include applying an electronic signature, a uniquely assigned username and password that together will represent a traditional handwritten signature.

The monitor will visit the study site on a regular basis to perform Source Data Verification (SDV) and/or will perform remote checks to ensure that the study is conducted and documented in accordance with this protocol, ICH GCP guidelines, regulatory requirements and any study specific documents such as eCRF completion guidelines.

Monitoring visits or remote monitoring will be conducted to confirm that e.g.:

- The investigational team is adhering to the study protocol
- Informed consent has been adequately obtained from all participants prior to study specific procedures being performed
- AEs have been reported and followed up as required and any SAEs have been reported according to the requirements
- Data are being accurately recorded in the eCRFs in a timely manner

- The Investigator's Site File is being adequately maintained
- Facilities and staffing resources are, and remain, acceptable and sufficient throughout the study
- The Investigator and the site are receiving sufficient information and support throughout the study

Moreover, during on-site monitoring visits the data recorded in the eCRFs, source documents and other study-related records will be compared against each other in order to ensure accurate data that reflect the actual existence of the subject in the study i.e. source data verification.

Monitoring procedures are described in the concerned Standard Procedural Documents of the CRO in charge and in the Monitoring Plan, which also encompasses situational changes, e.g. intermediate switch to remote monitoring only if site visits are not possible; details concerning the nature and extent of SDV are also provided in the Monitoring Plan.

12.3. ACCESS TO RECORDS

The Investigator will allow designated Sponsor representatives, including staff from the CRO, and regulatory/ethics bodies to have direct access to the source documents to verify the data reported in the eCRFs. Source documents are the originals of any documents used by the Investigator or hospital/institution that allow verification of the existence of the patient and substantiate the integrity of the data collected during the trial.

12.4. AUDIT AND INSPECTION

The study site may be audited by Sponsor or delegate or inspected by a regulatory agency on one or more occasions. The Investigator may be informed in advance of such a visit.

12.5. PROTOCOL AMENDMENTS

Any amendment to this protocol will be provided to the PI in writing by Dompé farmaceutici s.p.a., the Sponsor. No protocol amendment may be implemented (with the exceptions noted below) before it has been approved by the IRB/IEC and the signature page, signed by the PI, has been received by Dompé farmaceutici s.p.a. If the protocol is amended to eliminate or reduce the risk to patients, the amendment may be implemented before IRB/IEC review and approval. However, the IRB/IEC must be informed in writing of such an amendment, and approval must be obtained within reasonable time limits. Deviating from the protocol is permitted only if absolutely necessary for the safety or clinical management of the patients and must immediately be reported to Dompé farmaceutici s.p.a.

12.6. DISCONTINUATION OF THE STUDY

Dompé farmaceutici S.p.A. as Sponsor, reserves the right to terminate the study in its entirety or at a specific study center at any time on the basis of new information regarding safety or efficacy, or if study progress is unsatisfactory for whatever reason (including epidemics), or for other valid administrative reasons.

12.7. PUBLICATIONS

All data generated in this study will be the property of Dompé farmaceutici S.p.A. Publication of the results by the PI will be subject to mutual agreement between the PI and Dompé farmaceutici S.p.A.

The Sponsor agrees that the study results (including negative and inconclusive as well as positive results) can be made publicly available by the Investigator publishing in peer reviewed journals; presenting results at scientific congresses; and posting information and results on internet-based public registers and databases.

In any case, study results will be communicated in full to the related competent authorities for the countries involved by the submission of a complete Clinical Study Report.

As the Sponsor agrees that the study results can be published by the Investigator(s), the Investigator agrees to submit any manuscript (abstract, publication, paper etc.) to the Sponsor before any public disclosure.

This will be done in order to ensure that clinical trial results are reported in an objective, accurate and balanced manner. The Sponsor reviews proposed manuscripts prior to submission within a reasonable period of time (30-90 business days in relation with the complexity of the work).

The Investigator(s) will also be provided by the Sponsor with the clinical study report and the results of any additional analysis, tables, figures etc undertaken for the purposes of the article, in order to take responsibility for the content of the publication(s).

On an exceptional basis, the Sponsor may temporarily delay registration of certain data elements (e.g. compound, name, outcome, measures etc.) to seek necessary intellectual property protection. This is because early disclosure of such a data could, in some circumstances, prevent or negatively impact patentability.

13. REFERENCES

1. Pflugfelder, S. C. Prevalence, burden, and pharmacoeconomics of dry eye disease. *Am. J. Manag. Care* **14**, S102-106 (2008).
2. Craig, J. P. *et al.* TFOS DEWS II Definition and Classification Report. *Ocul. Surf.* **15**, 276–283 (2017).
3. Lambiase, A., Sacchetti, M. & Bonini, S. Nerve growth factor therapy for corneal disease. *Curr. Opin. Ophthalmol.* **23**, 296–302 (2012).
4. Lambiase, A., Bonini, S., Aloe, L., Rama, P. & Bonini, S. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. *Arch. Ophthalmol. Chic. Ill 1960* **118**, 1446–1449 (2000).
5. Nguyen, D. H., Beuerman, R. W., Thompson, H. W. & DiLoreto, D. A. Growth factor and neurotrophic factor mRNA in human lacrimal gland. *Cornea* **16**, 192–199 (1997).
6. Ghinelli, E. *et al.* Presence and localization of neurotrophins and neurotrophin receptors in rat lacrimal gland. *Invest. Ophthalmol. Vis. Sci.* **44**, 3352–3357 (2003).
7. Vesaluoma, M. *et al.* Effects of oleoresin capsicum pepper spray on human corneal morphology and sensitivity. *Invest. Ophthalmol. Vis. Sci.* **41**, 2138–2147 (2000).
8. Coassin, M. *et al.* Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. *Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.* **243**, 151–155 (2005).
9. Lee, H. K. *et al.* Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. *Ophthalmology* **113**, 198–205 (2006).
10. Bonini, S., Lambiase, A., Rama, P., Caprioglio, G. & Aloe, L. Topical treatment with nerve growth factor for neurotrophic keratitis. *Ophthalmology* **107**, 1347–1351; discussion 1351-1352 (2000).

11. Ríos, J. D., Ghinelli, E., Gu, J., Hodges, R. R. & Dartt, D. A. Role of neurotrophins and neurotrophin receptors in rat conjunctival goblet cell secretion and proliferation. *Invest. Ophthalmol. Vis. Sci.* **48**, 1543–1551 (2007).
12. McMonnies, C. W. Aqueous deficiency is a contributor to evaporation-related dry eye disease. *Eye Vis.* **7**, 6 (2020).
13. Leonard, B. C. *et al.* Comprehensive Clinical, Diagnostic, and Advanced Imaging Characterization of the Ocular Surface in Spontaneous Aqueous Deficient Dry Eye Disease in Dogs. *Cornea* **38**, 1568–1575 (2019).
14. Stern, M. E. & Pflugfelder, S. C. Inflammation in dry eye. *Ocul. Surf.* **2**, 124–130 (2004).
15. Pflugfelder, S. C. Antiinflammatory therapy for dry eye. *Am. J. Ophthalmol.* **137**, 337–342 (2004).
16. Labetoulle, M. *et al.* Role of corneal nerves in ocular surface homeostasis and disease. *Acta Ophthalmol. (Copenh.)* **97**, 137–145 (2019).
17. Mastropasqua, L., Massaro-Giordano, G., Nubile, M. & Sacchetti, M. Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal Nerves. *J. Cell. Physiol.* **232**, 717–724 (2017).
18. Lambiase, A., Rama, P., Bonini, S., Caprioglio, G. & Aloe, L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. *N. Engl. J. Med.* **338**, 1174–1180 (1998).
19. Niederkorn, JY, Stern ME, Pflugfelder SC, *et al.* Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. *J Immunol.* **176**, 3950– 3957 (2006).
20. Periman LM, Mah FS, Karpecki PM. A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments. *Clin Ophthalmol.* **14**, 4187–4200 (2020).

21. Ames P, Galor A. Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. *Clin Investig (Lond)* 5(3), 267-285 (2015).
22. Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. *Curr Med Res Opin.* 21(7), 1057-63 (2005).
23. FDA Drug Approval package: Restasis (cyclosporin ophthalmic emulsion).
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis_Approv.PDF. Published 2003. Accessed June 11, 2021.
24. De Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. *Cochrane Database of Systematic Reviews Issue 9. Art. No.: CD010051* (2019).
25. Fondi K, Mihaltz K, Vecsei-Marlovits PV. Efficacy of topical hydrocortisone in combination with topical ciclosporin A for the treatment of dry eye disease in patients with Sjogren Syndrome. *J Ophthalmol* **2021**, 7584370 (2021).
26. Cubuk MO, Uegul AY, Ozgur A, Ozulken A, Yuksel E. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome. *Int Ophthalmol* **41**, 1479-1485 (2021).
27. Vitali, C. et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann. Rheum. Dis.* 61, 554–558 (2002).

14 APPENDICES

14.1 APPENDIX 1-SPONSOR APPROVAL PAGE

NGF0221 (PROTEGO-2 study): A 4 week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren's dry eye disease under treatment with Cyclosporine A

Sponsor Medical Expert:

PPD

Date: ____/____/____

PPD

Sponsor Chief Medical Officer

PPD

Date: ____/____/____

PPD

Sponsor Clinical Trial Manager:

PPD

Date: ____/____/____

PPD

14.2 APPENDIX 2-INVESTIGATOR'S SIGNATURE PAGE

Investigator's Statement

I have read study protocol NGF0221 (*PROTEGO-2*) from the title “*A 4 week, Phase III, multicenter, double-masked, vehicle-controlled clinical study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren's dry eye disease under treatment with Cyclosporine A (PROTEGO-2)*” and agree to conduct the study as outlined in the protocol, and in accordance with the Declaration of Helsinki, ICH-GCP E6 (R2) and any local regulations, being responsible for personally supervise the study conduct and ensure study staff complies with protocol requirement.

Name of Principal Investigator (block letters): _____

Signature: _____

Date: _____

14.3 APPENDIX 3 AMERICAN-EUROPEAN CONSENSUS CRITERIA FOR SJÖGREN'S SYNDROME

Reference: Vitali C, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002; 61:554-558.²⁷

In order to make a diagnosis of Sjögren's syndrome, the following criteria must be met:

I. Ocular Symptoms (at least one)

- Symptoms of dry eyes for at least 3 months
- A foreign body sensation in the eyes
- Use of artificial tears 3 or more times per day

II. Oral Symptoms (at least one)

- Symptoms of dry mouth for at least 3 months
- Recurrent or persistently swollen salivary glands
- Need for liquids to swallow dry foods

III. Ocular Signs (at least one)

- Abnormal Schirmer's test, (without anesthesia; ≤ 5 mm/5 minutes)
- Positive vital dye staining of the eye surface

IV. Histopathology

- Lip biopsy showing focal lymphocytic sialoadenitis (focus score ≥ 1 per 4 mm²)

V. Oral Signs (at least one)

- Unstimulated whole salivary flow (≤ 1.5 mL in 15 minutes)
- Abnormal parotid sialography
- Abnormal salivary scintigraphy

VI. Autoantibodies (at least one)

- Anti-SSA (Ro) or Anti-SSB (La), or both

For a primary Sjögren's syndrome diagnosis:

- Any 4 of the 6 criteria, must include either item IV (Histopathology) or VI (Autoantibodies)
- Any 3 of the 4 objective criteria (III, IV, V, VI)

For a secondary Sjögren's syndrome diagnosis:

- In patients with another well-defined major connective tissue disease, the presence of one symptom (I or II) plus 2 of the 3 objective criteria (III, IV and V) is indicative of secondary SS.

Exclusion Criteria

- Past head and neck radiation treatment
- Hepatitis C infection
- Acquired immunodeficiency syndrome (AIDS)
- Pre-existing lymphoma
- Sarcoidosis
- Graft versus host disease
- Current use of anticholinergic drugs